"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05006573","Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis","MAHALE","Recruiting","No Results Available","Non-cystic Fibrosis Bronchiectasis","Biological: Benralizumab|Biological: Placebo to Benralizumab","Annualised exacerbation rate|Time to first bronchiectasis exacerbation|Change from baseline in QoL-B-RSS|Change from baseline in pre-dose FEV1|Change from baseline in LCQ|Annualised rate of severe bronchiectasis exacerbations|Annualised rate of hospitalisations due to bronchiectasis exacerbations|Frequency of antibiotic use for bronchiectasis exacerbations|Change from baseline in QoL-B scales (excluding QoL-B-RSS key secondary endpoint)|Change from baseline in SGRQ|Frequency and annual rate of NCFB-related healthcare encounters|Frequency and annual rate of NCFB-related tests/procedures|Total hospital length of stay per healthcare encounter|Safety and tolerability of benralizumab","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D325BC00001|2020-004068-24","July 21, 2021","June 10, 2024","January 5, 2026","August 16, 2021",,"June 8, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Denver, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Hinesville, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Rincon, Georgia, United States|Research Site, Kansas City, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Statesville, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, El Paso, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Florida, Argentina|Research Site, San Fernando, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Concord, Australia|Research Site, Melbourne, Australia|Research Site, Parkville, Australia|Research Site, South Brisbane, Australia|Research Site, Sydney, Australia|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Cangzhou, China|Research Site, Changsha, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hohhot, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xinxiang, China|Research Site, Xuzhou, China|Research Site, Xuzhou, China|Research Site, Yangzhou, China|Research Site, Zhengzhou, China|Research Site, Zunyi, China|Research Site, Aalborg, Denmark|Research Site, Hellerup, Denmark|Research Site, Hvidovre, Denmark|Research Site, Køge, Denmark|Research Site, Vejle, Denmark|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Borstel, Germany|Research Site, Donaustauf, Germany|Research Site, Düsseldorf, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Hessen, Germany|Research Site, München, Germany|Research Site, Coimbatore, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, Noida, India|Research Site, Bari, Italy|Research Site, Catania, Italy|Research Site, Foggia, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Poznań, Poland|Research Site, Sosnowiec, Poland|Research Site, Wejherowo, Poland|Research Site, Wrocław, Poland|Research Site, Chelyabinsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Cambridge, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT05006573"
2,"NCT05344508","An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis",,"Available","No Results Available","Non-Cystic Fibrosis Bronchiectasis","Drug: Brensocatib",,"Insmed Incorporated","All","18 Years to 85 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"INS1007-EAP",,,,"April 25, 2022",,"April 25, 2022",,,"https://ClinicalTrials.gov/show/NCT05344508"
3,"NCT02081963","Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis",,"Completed","Has Results","Non-Cystic Fibrosis Bronchiectasis","Drug: Amikacin|Drug: Normal saline","Bacterial Clearance Rate of Sputum|Total Sputum Weight (Collected Over 24 h) After 14 Days of Treatment|Sputum Property Score After 14 Days of Treatment|Forced Expiratory Volume in One Second (FEV1) (Percent of Predicted for Age) After 14 Days of Treatment|Forced Expiratory Volume in One Second (FEV1) After 14 Days of Treatment","Qilu Hospital of Shandong University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","178","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCFB-AMK-01","March 2014","March 2016","December 2016","March 7, 2014","April 16, 2019","April 24, 2019","Qilu Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT02081963"
4,"NCT04278040","Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis","SEADIB1","Unknown status","No Results Available","Non-cystic Fibrosis Bronchiectasis","Drug: Melphalan","Frequency of drug-related side effects.|The changes of The St George's Respiratory Questionnaire (SGRQ)|The changes of The Quality of Life-Bronchiectasis (QOL-B) questionnaire","Federal State Budgetary Institution, Pulmonology Scientific Research Institute|Moscow State University of Medicine and Dentistry","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSRI02-18","June 20, 2018","December 1, 2021","December 30, 2021","February 20, 2020",,"February 20, 2020","Kirill Zykov, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04278040"
5,"NCT04594369","A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis","ASPEN","Recruiting","No Results Available","Non-Cystic Fibrosis Bronchiectasis","Drug: Brensocatib 10 mg|Drug: Brensocatib 25 mg|Drug: Placebo","Rate of Adjudicated Pulmonary Exacerbations (PEs)|Time to First Adjudicated Pulmonary Exacerbation (PE)|Percentage of Participants who are Pulmonary Exacerbation (PE) Free|Change From Baseline in Postbronchodilator Forced Expiratory Volume in 1 second (FEV1)|Rate of Severe Adjudicated Pulmonary Exacerbations (PEs)|Change from Baseline to Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants|Number of Participants who Experience at Least one Treatment-Emergent Adverse Events (TEAEs)|Plasma Concentration of Brensocatib at Select Time Points","Insmed Incorporated","All","12 Years to 85 Years   (Child, Adult, Older Adult)","Phase 3","1620","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","INS1007-301|2020-003688-25","December 1, 2020","March 22, 2024","March 22, 2024","October 20, 2020",,"June 8, 2022","USA013, Birmingham, Alabama, United States|USA080, Conway, Arkansas, United States|USA044, Little Rock, Arkansas, United States|USA104, Fresno, California, United States|USA086, Los Angeles, California, United States|USA055, Los Angeles, California, United States|USA029, Newport Beach, California, United States|USA102, Northridge, California, United States|USA022, Palm Springs, California, United States|USA042, Palm Springs, California, United States|USA024, Sacramento, California, United States|USA057, San Diego, California, United States|USA035, San Diego, California, United States|USA078, Santa Barbara, California, United States|USA027, Ventura, California, United States|USA075, Denver, Colorado, United States|USA008, Lafayette, Colorado, United States|USA017, Farmington, Connecticut, United States|USA001, Washington, District of Columbia, United States|USA054, Brandon, Florida, United States|USA015, Clearwater, Florida, United States|USA062, Fort Lauderdale, Florida, United States|USA076, Gainesville, Florida, United States|USA032, Jacksonville, Florida, United States|USA082, Jacksonville, Florida, United States|USA007, Kissimmee, Florida, United States|USA039, Kissimmee, Florida, United States|USA072, Leesburg, Florida, United States|USA019, Miami Lakes, Florida, United States|USA037, Miami, Florida, United States|USA049, Naples, Florida, United States|USA106, New Port Richey, Florida, United States|USA108, Orlando, Florida, United States|USA052, Orlando, Florida, United States|USA103, Plantation, Florida, United States|USA089, Saint Petersburg, Florida, United States|USA074, Saint Petersburg, Florida, United States|USA084, Sarasota, Florida, United States|USA058, Sebring, Florida, United States|USA012, Atlanta, Georgia, United States|USA053, Augusta, Georgia, United States|USA077, Rincon, Georgia, United States|USA073, Chicago, Illinois, United States|USA061, Maywood, Illinois, United States|USA063, Iowa City, Iowa, United States|USA031, Kansas City, Kansas, United States|USA020, New Orleans, Louisiana, United States|USA051, New Orleans, Louisiana, United States|USA003, Baltimore, Maryland, United States|USA047, Columbia, Maryland, United States|USA025, Towson, Maryland, United States|USA079, Boston, Massachusetts, United States|USA064, Springfield, Massachusetts, United States|USA090, Worcester, Massachusetts, United States|USA010, Rochester, Minnesota, United States|USA006, Chesterfield, Missouri, United States|USA059, Saint Louis, Missouri, United States|USA110, Lincoln, Nebraska, United States|USA009, Omaha, Nebraska, United States|USA065, Toms River, New Jersey, United States|USA095, Bronx, New York, United States|USA066, New Hyde Park, New York, United States|USA021, New York, New York, United States|USA085, New York, New York, United States|USA068, Potsdam, New York, United States|USA014, Chapel Hill, North Carolina, United States|USA048, Charlotte, North Carolina, United States|USA033, Gastonia, North Carolina, United States|USA096, Huntersville, North Carolina, United States|USA026, Winston-Salem, North Carolina, United States|USA067, Cincinnati, Ohio, United States|USA028, Cleveland, Ohio, United States|USA093, Cleveland, Ohio, United States|USA023, Portland, Oregon, United States|USA038, DuBois, Pennsylvania, United States|USA046, Philadelphia, Pennsylvania, United States|USA071, Anderson, South Carolina, United States|USA005, Charleston, South Carolina, United States|USA036, Rock Hill, South Carolina, United States|USA041, Franklin, Tennessee, United States|USA097, Dallas, Texas, United States|USA087, Galveston, Texas, United States|USA050, McKinney, Texas, United States|USA018, Mesquite, Texas, United States|USA011, San Antonio, Texas, United States|USA002, Tyler, Texas, United States|USA081, Salt Lake City, Utah, United States|USA034, Williamsburg, Virginia, United States|USA088, Vancouver, Washington, United States|ARG021, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|ARG022, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|ARG002, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|ARG001, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|ARG003, Ciudad Autónoma de BuenosAires, Buenos Aires, Argentina|ARG004, Ciudad Autónoma de BuenosAires, Buenos Aires, Argentina|ARG006, la Plata, Buenos Aires, Argentina|ARG013, Mar del Plata, Buenos Aires, Argentina|ARG017, Mar Del Plata, Buenos Aires, Argentina|ARG009, Villa Vatteone, Buenos Aires, Argentina|ARG012, Ciudad Autónoma de Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|ARG018, Ciudad Autónoma de Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|ARG014, City Of Mendoza, Mendoza, Argentina|ARG016, Rosario, Santa Fe, Argentina|ARG010, Rosario, Santa Fe, Argentina|ARG015, San Miguel de Tucumán, Tucumán, Argentina|ARG008, San Miguel de Tucumán, Tucumán, Argentina|ARG005, Córdoba, Argentina|ARG007, Mendoza, Argentina|ARG011, Rosario, Argentina|ARG019, Santa Fe, Argentina|AUS013, Kogarah, New South Wales, Australia|AUS008, New Lambton Heights, New South Wales, Australia|AUS007, Westmead, New South Wales, Australia|AUS012, Cairns North, Queensland, Australia|AUS001, Chermside, Queensland, Australia|AUS010, Greenslopes, Queensland, Australia|AUS006, South Brisbane, Queensland, Australia|AUS011, Adelaide, South Australia, Australia|AUS017, Bedford Park, South Australia, Australia|AUS004, Kent Town, South Australia, Australia|AUS009, Woodville South, South Australia, Australia|AUS002, Box Hill, Victoria, Australia|AUS014, Clayton, Victoria, Australia|AUS018, Murdoch, Western Australia, Australia|AUS005, Nedlands, Western Australia, Australia|AUS003, Concord, Australia|AUS015, Spearwood, Australia|AUT001, Graz, Steiermark, Austria|AUT002, Linz, Austria|BEL002, Gent, Oost-Vlaanderen, Belgium|BEL004, Roeselare, West-Vlaanderen, Belgium|BEL006, Brussels, Belgium|BEL005, Edegem, Belgium|BEL001, Leuven, Belgium|BEL007, Liège, Belgium|BEL003, Mechelen, Belgium|BEL008, Sint-Niklaas, Belgium|BRA009, Passo Fundo, Rio Grande Do Sul, Brazil|BRA005, Porto Alegre, Rio Grande Do Sul, Brazil|BRA001, Blumenau, Santa Catarina, Brazil|BRA002, Santo André, São Paulo, Brazil|BRA006, Santo André, São Paulo, Brazil|BRA003, Botucatu, Brazil|BRA004, São Bernardo do Campo, Brazil|BRA010, São Paulo, Brazil|BGR011, Sofia, Sofia-Grad, Bulgaria|BGR009, Sofia, Sofia-Grad, Bulgaria|BGR002, Sofia, Sofia-Grad, Bulgaria|BGR005, Blagoevgrad, Bulgaria|BGR006, Gabrovo, Bulgaria|BGR014, Kozloduy, Bulgaria|BGR015, Lovech, Bulgaria|BGR007, Montana, Bulgaria|BGR018, Pazardzhik, Bulgaria|BGR019, Pleven, Bulgaria|BGR004, Plovdiv, Bulgaria|BGR008, Ruse, Bulgaria|BGR017, Sliven, Bulgaria|BGR010, Sofia, Bulgaria|BGR012, Veliko Tarnovo, Bulgaria|BGR013, Vidin, Bulgaria|BGR016, Vratsa, Bulgaria|CAN004, Toronto, Ontario, Canada|CAN002, Montreal, Quebec, Canada|CAN003, Saint-Charles-Borromée, Quebec, Canada|CHL007, Valdivia, Los Ríos, Chile|CHL005, Curicó, Maule, Chile|CHL010, Talca, Maule, Chile|CHL001, Providencia, Región-MetropolitanadeSantiago, Chile|CHL002, Providencia, Región-MetropolitanadeSantiago, Chile|CHL008, Providencia, Región-MetropolitanadeSantiago, Chile|CHL004, Quillota, Chile|COL007, Medellín, Antioquia, Colombia|COL006, Zipaquira, Cundinamarca, Colombia|COL001, Bogotá, Distrito Capital De Bogotá, Colombia|COL005, Floridablanca, Santander, Colombia|COL003, Cali, Valle Del Cauca, Colombia|COL004, Cali, Colombia|DNK001, Hvidovre, Capital, Denmark|DNK005, Odense C, South Denmark, Denmark|DNK006, Vejle, South Denmark, Denmark|DNK003, Aalborg, Denmark|DNK007, Aarhus, Denmark|DNK004, Hellerup, Denmark|DNK002, Roskilde, Denmark|FRA002, Strasbourg, Bas-Rhin, France|FRA005, Montpellier, Hérault, France|FRA001, Tours, Indre-et-Loire, France|FRA004, Amiens cedex 1, France|FRA011, Creteil, France|FRA003, Nantes, France|FRA009, Nice, France|FRA010, Paris, France|FRA008, Saint-Pierre, France|FRA006, Toulouse, France|DEU009, Heidelberg, Baden-Württemberg, Germany|DEU001, Donaustauf, Bayern, Germany|DEU025, München, Bayern, Germany|DEU012, München, Bayern, Germany|DEU027, Potsdam, Brandenburg, Germany|DEU004, Frankfurt am Main, Hessen, Germany|DEU008, Frankfurt, Hessen, Germany|DEU005, Marburg, Hessen, Germany|DEU026, Marburg, Hessen, Germany|DEU018, Neu-Isenburg, Hessen, Germany|DEU010, Borstel, Niedersachsen, Germany|DEU013, Essen, Nordrhein-Westfalen, Germany|DEU024, Homburg, Saarland, Germany|DEU016, Halle, Sachsen-Anhalt, Germany|DEU003, Leipzig, Sachsen, Germany|DEU020, Geesthacht, Schleswig-Holstein, Germany|DEU007, Lübeck, Schleswig-Holstein, Germany|DEU028, Berlin, Germany|DEU002, Berlin, Germany|DEU019, Berlin, Germany|DEU006, Berlin, Germany|DEU011, Berlin, Germany|DEU014, Dresden, Germany|DEU021, Frankfurt, Germany|DEU022, Hannover, Germany|DEU015, Hannover, Germany|DEU023, Mainz, Germany|DEU029, Muenster, Germany|GRC003, Alexandroupoli, Evros, Greece|GRC002, Larissa, Larisa, Greece|GRC007, Herakleion, Greece|GRC006, Thessaloniki, Greece|HUN005, Tatabánya, Komárom-Esztergom, Hungary|IRL003, Dublin, Ireland|IRL004, Dublin, Ireland|IRL002, Dublin, Ireland|IRL001, Limerick, Ireland|ISR005, Holon, Tel-Aviv, Israel|ISR001, Ashkelon, Israel|ISR010, Beer Sheva, Israel|ISR008, Haifa, Israel|ISR006, Jerusalem, Israel|ISR002, Jerusalem, Israel|ISR009, Kefar-Sava, Israel|ISR011, Petach Tikva, Israel|ISR007, Ramat Gan, Israel|ISR003, Rehovot, Israel|ISR004, Zerifin, Israel|ITA010, Bologna, Emilia-Romagna, Italy|ITA008, Ferrara, Emilia-Romagna, Italy|ITA002, Reggio Emilia, Emilia-Romagna, Italy|ITA006, Milano, Lombardia, Italy|ITA011, Rozzano, Lombardia, Italy|ITA004, Siena, Toscana, Italy|ITA003, Milano, Italy|ITA001, Palermo, Italy|ITA007, Pavia, Italy|ITA009, Roma, Italy|JPN029, Toyoake, Aiti, Japan|JPN026, Akita-Shi, Akita, Japan|JPN031, Toon-Shi, Ehime, Japan|JPN027, Fukuoka-Shi, Hukuoka, Japan|JPN023, Iizuka-Shi, Hukuoka, Japan|JPN021, Kitakyushu-Shi, Hukuoka, Japan|JPN025, Yanagawa-Shi, Hukuoka, Japan|JPN009, Kobe-City, Hyôgo, Japan|JPN020, Kasama-Shi, Ibaraki, Japan|JPN001, Naka-gun, Ibaraki, Japan|JPN022, Takamatsu-Shi, Kagawa, Japan|JPN028, Yokohama-Shi Konan-Ku, Kanagawa, Japan|JPN005, Koshi shi, Kumamoto, Japan|JPN008, Matsusaka-shi, Mie, Japan|JPN011, Tsu, Mie, Japan|JPN024, Sendai-shi, Miyagi, Japan|JPN013, Nagasaki-Shi, Nagasaki, Japan|JPN012, Chuo-ku, Niigata, Japan|JPN015, Matsue, Simane, Japan|JPN007, Kiyose, Tokyo, Japan|JPN014, Ota-Ku, Tokyo, Japan|JPN006, Shinagawa-ku, Tokyo, Japan|JPN017, Shinagawa-ku, Tokyo, Japan|JPN002, Shinjuku-ku, Tokyo, Japan|JPN019, Shimonoseki-Shi, Yamaguti, Japan|JPN030, Fukuoka-shi, Japan|JPN003, Hamamatsu-Shi, Japan|JPN004, Kita Kyushu-shi, Japan|JPN016, Matsue-shi, Japan|JPN010, Meguro-ku, Japan|JPN033, Sakai-shi, Japan|JPN018, Toyonaka-shi, Japan|KOR015, Ansan-si, Gyeonggido, Korea, Republic of|KOR008, Bucheon-si, Gyeonggido, Korea, Republic of|KOR007, Seongnam-si, Gyeonggido, Korea, Republic of|KOR014, Uijeongbu-Si, Gyeonggido, Korea, Republic of|KOR003, Seoul, Seoul Teugbyeolsi, Korea, Republic of|KOR004, Incheon, Korea, Republic of|KOR001, Incheon, Korea, Republic of|KOR002, Incheon, Korea, Republic of|KOR012, Seoul, Korea, Republic of|KOR011, Seoul, Korea, Republic of|KOR006, Seoul, Korea, Republic of|KOR009, Seoul, Korea, Republic of|KOR013, Seoul, Korea, Republic of|KOR010, Seoul, Korea, Republic of|KOR005, Seoul, Korea, Republic of|LVA002, Daugavpils, Daugavpils Aprinkis, Latvia|LVA005, Jurmala, Latvia|MYS004, Kuantan, Pahang, Malaysia|MYS006, Kuching, Sarawak, Malaysia|MYS002, Bandar Puncak Alam, Selangor, Malaysia|MYS001, Kuala Lumpur, WilayahPersekutuan KualaLumpur, Malaysia|MYS003, Kota Bahru, Malaysia|MYS005, Kuala Lumpur, Malaysia|MEX007, Guadalajara, Jalisco, Mexico|MEX008, Guadalajara, Jalisco, Mexico|MEX005, Guadalajara, Jalisco, Mexico|MEX004, Guadalajara, Jalisco, Mexico|MEX003, Monterrey, Nuevo León, Mexico|MEX006, Durango, Mexico|MEX001, Monterrey, Mexico|MEX002, Oaxaca, Mexico|NLD003, Arnhem, Gelderland, Netherlands|NLD001, Alkmaar, Noord-Holland, Netherlands|NLD002, Amsterdam, Noord-Holland, Netherlands|NLD004, Den Haag, Zuid-Holland, Netherlands|NLD005, Heerlen, Netherlands|NLD006, Rotterdam, Netherlands|NZL006, Otahuhu, Auckland, New Zealand|NZL005, Christchurch, South Island, New Zealand|NZL001, Dunedin, South Island, New Zealand|NZL002, Hamilton, Waikato, New Zealand|NZL011, Paraparaumu, Wellington, New Zealand|NZL003, Auckland, New Zealand|NZL008, Auckland, New Zealand|NZL004, Auckland, New Zealand|NZL009, Havelock North, New Zealand|NZL007, Tauranga, New Zealand|NZL010, Wellington, New Zealand|PER008, La Victoria, Lima, Peru|PER005, Chancay, Peru|PER001, Lima, Peru|PER003, Lima, Peru|PER002, Lima, Peru|PER006, Piura, Peru|PER004, San Miguel, Peru|POL012, Ostrowiec Swietokrzyski, Swietokrzyskie, Poland|POL005, Bialystok, Poland|POL006, Bielsko Biala, Poland|POL016, Katowice, Poland|POL015, Kielce, Poland|POL017, Krakow, Poland|POL018, Ksawerow, Poland|POL008, Rabka-Zdroj, Poland|POL011, Rzeszów, Poland|POL010, Siedlce, Poland|POL007, Sosnowiec, Poland|POL001, Sucha Beskidzka, Poland|POL014, Szczecin, Poland|POL009, Tarnow, Poland|PRT004, Loures, Lisboa, Portugal|PRT005, Aveiro, Portugal|PRT009, Braga, Portugal|PRT001, Covilhã, Portugal|PRT006, Guarda, Portugal|PRT002, Guimaraes, Portugal|PRT003, Lisboa, Portugal|PRT007, Vila Nova de Gaia, Portugal|SRB001, Belgrade, Serbia|SRB003, Belgrade, Serbia|SRB007, Nis, Serbia|SRB014, Sombor, Serbia|SRB010, Uzice, Serbia|SVK002, Bardejov, Slovakia|SVK003, Spisská Nová Ves, Slovakia|ESP009, Santiago de Compostela, A Coruña, Spain|ESP008, Oviedo, Asturias, Spain|ESP013, Badalona, Barcelona, Spain|ESP012, Santander, Cantabria, Spain|ESP015, Pozuelo de Alarcon, Madrid, Spain|ESP011, Pamplona, Navarra, Spain|ESP003, Barcelona, Spain|ESP016, Barcelona, Spain|ESP001, Girona, Spain|ESP006, L´Hospitalet de Llobregat, Spain|ESP007, Madrid, Spain|ESP002, Madrid, Spain|TWN003, Kaohsiung City, Taiwan|TWN002, Kaohsiung, Taiwan|TWN001, Kaohsiung, Taiwan|TWN005, New Taipei City, Taiwan|TWN006, Taipei City, Taiwan|TWN007, Taipei, Taiwan|TWN004, Taipei, Taiwan|THA004, Nakhonnayok, Nakhon Nayok, Thailand|THA002, Muang, Nonthaburi, Thailand|THA001, Bangkok, Thailand|THA003, Khon Kaen, Thailand|TUR006, Atakum, Samsun, Turkey|TUR010, Ankara, Turkey|TUR011, Ankara, Turkey|TUR003, Canakkale, Turkey|TUR008, Izmir, Turkey|TUR004, Izmir, Turkey|TUR009, Kocaeli, Turkey|TUR005, Konya, Turkey|TUR001, Mersin, Turkey|UKR001, Kharkiv, Kharkivs'ka Oblast, Ukraine|UKR007, Kherson, Khersons'ka Oblast, Ukraine|UKR005, Poltava, Poltavs'ka Oblast, Ukraine|UKR012, Dnipro, Ukraine|UKR009, Ivano-Frankivsk, Ukraine|UKR008, Kyiv, Ukraine|UKR004, Kyiv, Ukraine|UKR003, Odesa, Ukraine|UKR010, Vinnytsia, Ukraine|GBR001, Cambridge, Cambridgeshire, United Kingdom|GBR015, Exeter, Devon, United Kingdom|GBR017, Norwich, Norfolk, United Kingdom|GBR013, Llandough, Penarth, Vale Of Glamorgan, The, United Kingdom|GBR016, Bradford, Yorkshire, United Kingdom|GBR006, Birmingham, United Kingdom|GBR002, Chertsey, United Kingdom|GBR007, Dundee, United Kingdom|GBR004, Liverpool, United Kingdom|GBR014, Londonderry, United Kingdom|GBR009, London, United Kingdom|GBR008, Manchester, United Kingdom|GBR011, Manchester, United Kingdom|GBR003, Newcastle upon Tyne, United Kingdom|GBR012, Salford, United Kingdom|GBR018, Southampton, United Kingdom|GBR010, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04594369"
6,"NCT04656275","A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation",,"Terminated","No Results Available","Non-cystic Fibrosis Bronchiectasis","Drug: BI 1323495|Drug: Placebo","Occurrence of drug-related adverse events|Change from baseline to week 12 in absolute neutrophil elastase (NE) activity in sputum|Change from baseline to week 12 in neutrophil cell count in sputum|Change from baseline to week 12 in NE activity in whole blood after stimulation with zymosan, normalized to neutrophil counts|Change from baseline to week 12 in absolute post-bronchodilator forced expiratory volume in one second (FEV1)","Boehringer Ingelheim","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1405-0008|2019-003853-27","March 4, 2021","December 20, 2021","December 20, 2021","December 7, 2020",,"March 23, 2022","IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany|Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany|KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany|Ninewells Hospital & Medical School, Dundee, United Kingdom|Liverpool Heart & Chest Hospital, Liverpool, United Kingdom|Medicines Evaluation Unit, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04656275"
7,"NCT01792427","Mortality in Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Non-cystic Fibrosis Bronchiectasis",,"overall survival|risk factor identification for NCFB","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)",,"253","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B51060|B32220084152","June 2006","October 2012","December 2012","February 15, 2013",,"February 20, 2013","UZ Leuven, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT01792427"
8,"NCT03460704","Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS II)",,"Completed","No Results Available","Non Cystic Fibrosis Bronchiectasis","Drug: Colistimethate sodium|Drug: Saline Solution","Annualized Pulmonary Exacerbation rate|Time to first pulmonary exacerbation|Annualised number of pulmonary exacerbation-free days|Number of severe NCFB pulmonary exacerbations,|Time to first severe pulmonary exacerbation|Quality of life (SGRQ)|Quality of Life (Qol-B)|Days of work absence|P. aeruginosa density","Zambon SpA","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Z7224L02","January 29, 2018","March 15, 2022","March 15, 2022","March 9, 2018",,"June 1, 2022","Zambon Investigative Site, Newport Beach, California, United States|Zambon Investigative Site, Palm Springs, California, United States|Zambon Investigative Site, Reseda, California, United States|Zambon Investigative Site, San Diego, California, United States|Zambon Investgative Site, San Diego, California, United States|Zambon Investigative Site, Centennial, Colorado, United States|Zambon Investigative Site, Jacksonville, Florida, United States|Zambon Investigative Site, Kissimmee, Florida, United States|Zambon Investigative Site, Orlando, Florida, United States|Zambon investigative Site, Saint Petersburg, Florida, United States|Zambon Investigative Site, Saint Petersburg, Florida, United States|Zambon Investigative Site, Weston, Florida, United States|Zambon Investigative Site, Chicago, Illinois, United States|Zambon Investigative Site, Michigan City, Indiana, United States|Zambon Investigative Site, Louisville, Kentucky, United States|Zambon Investigative Site, Rochester, Minnesota, United States|Zambon Investigative Site, Chesterfield, Missouri, United States|Zambon Investigative Site, Lebanon, New Hampshire, United States|ZambonInvestigative Site, New York, New York, United States|Zambon Investigative Site, Chapel Hill, North Carolina, United States|Zambon Investigative Site, Durham, North Carolina, United States|Zambon Investigative Site, Winston-Salem, North Carolina, United States|Zambon Investigative Site, Portland, Oregon, United States|Zambon Investigative Site, Tyler, Texas, United States|ZambonInvestigative Site, Abingdon, Virginia, United States|Zambon Investigative Site, Richmond, Virginia, United States|Zambon Investigative Site, Northwest, Washington, United States|Zambon Investigative Site, Buenos Aires, Argentina|Zambon Investigative Site, Buenos Aires, Argentina|Zambon Investigative Site, Buenos Aires, Argentina|Zambon Investigative Site, Buenos Aires, Argentina|Zambon Investigative Site, Buenos Aires, Argentina|Zambon Investigative Site, Buenos Aires, Argentina|Zambon Investigative Site, Ciudad Autónoma de Buenos Aires, Argentina|Zambon Investigative Site, Ciudad Autónoma de Buenos Aires, Argentina|Zambon Investigative Site, Quilmes, Argentina|Zambon Investigative Site, Santa Fe, Argentina|Zambon Investigative Site, Tucumán, Argentina|Zambon Investigative Site, Adelaide, Australia|Zambon Investigative Site, Brisbane, Australia|Zambon Investigative Site, Kent Town, Australia|Zambon Investigative Site, Murdoch, Australia|Zambon Investigative Site, South Brisbane, Australia|Zambon Investigative Site, Sydney, Australia|Zambon investigative Site, Burlington, Canada|Zambon Investigative Site, Kelowna, Canada|Zambon Investigative Site, London, Canada|Zambon Investigative Site, Montréal, Canada|Zambon Investigative Site, Ottawa, Canada|Zambon Investigative Site, Quebec City, Canada|Zambon Investigative Site, Winnipeg, Canada|Zambon Investigative Site, Amiens, France|Zambon Investigative Site, Brest, France|Zambon Investigative Site, Créteil, France|Zambon Investigative Site, Grenoble, France|Zambon Investigative Site, Lyon, France|Zambon Investigative Site, Montpellier, France|Zambon Investigative Site, Nice, France|Zambon Investigative Site, Pessac, France|Zambon Investigative Site, Reims, France|Zambon Investigative Site, Toulouse, France|Zambon Investigative Site, Frankfurt, Germany|Zambon Investigative Site, Hanover, Germany|Zambon Investigative Site, Athens, Greece|Zambon Investigative Site, Haifa, Israel|Zambon Investigative Site, Jerusalem, Israel|Zambon Investigative Site, Kfar Saba, Israel|Zambon Investigative Site, Milano, Italy|Zambon Investigative Site, Monza, Italy|Zambon Investigative Site, Christchurch, New Zealand|Zambon Investigative Site, Havelock North, New Zealand|Zambon Investigative Site, Mount Cook, New Zealand|Zambon Investigative Site, Tauranga, New Zealand|Zambon Investigative Site, Białystok, Poland|Zambon Investigative Site, Bielsko-Biala, Poland|Zambon Investigative Site, Cracovia, Poland|Zambon Investigative Site, Grudziądz, Poland|Zambon Investigative Site, Legnica, Poland|Zambon Investigative Site, Lublin, Poland|Zambon Investigative Site, Ostrowiec Świętokrzyski, Poland|Zambon Investigative Site, Piaseczno, Poland|Zambon Investigative Site, Proszowice, Poland|Zambon Investigative Site, Rzeszów, Poland|Zambon Investigative Site, Sosnowiec, Poland|Zambon Investigative Site, Warszawa, Poland|Zambon Investigative Site, Wrocław, Poland|Zambon Investigative Site, Łódź, Poland|Zambon Investigative Site, Guimarães, Portugal|Zambon Investigative Site, Lisboa, Portugal",,"https://ClinicalTrials.gov/show/NCT03460704"
9,"NCT02883101","The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Non-cystic Fibrosis Bronchiectasis","Behavioral: Pulmonary Rehabilitation","Exercise capacity|Cough related QoL|Health Related Quality of Life|Lung Functions|Anxiety and depressions score","All India Institute of Medical Sciences, New Delhi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IESC/T-345","June 2015","October 2016","December 2016","August 30, 2016",,"July 5, 2017","Dr. Rohit Kumar, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT02883101"
10,"NCT02712983","Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection","iBEST-1","Completed","Has Results","Non-cystic Fibrosis Bronchiectasis","Drug: TIP|Drug: TIP and placebo|Drug: Placebo","Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)|Change From Baseline to Each Post-baseline Visit in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs)|Time to First Onset of Pulmonary Exacerbation by Exacerbation Category|Duration of Pulmonary Exacerbation by Exacerbation Category|Exposure Adjusted Rate of Pulmonary Exacerbations (PE) Over the Entire Study Period|Percentage of Participants With at Least One Pulmonary Exacerbation by Exacerbation Category|Percentage of Participants Who Permanently Discontinued Study Drug Due to Pulmonary Exacerbation|Time to Permanent Study Drug Discontinuation Due to Pulmonary Exacerbation|Time to First Use (Overall, Oral, and Parenteral) of Anti-pseudomonal Antibiotics Usage|Percentage of Participants Requiring Anti-pseudomonal Antibiotics|Duration of Anti-pseudomonal Antibiotics Usage|Percentage of Participants Requiring Hospitalization Due to Serious Respiratory-related Adverse Events|Duration of Hospitalization Due to Serious Respiratory-related Adverse Events|Number of Hospitalization Due to Serious Respiratory-related Adverse Events|Time to First Hospitalization Due to Serious Respiratory-related Adverse Events|Serum Tobramycin Concentration|Sputum Tobramycin Concentration|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Physical Functioning|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Role Functioning|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Vitality|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Emotional Functioning|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Social Functioning|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Treatment Burden|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Health Perceptions|Change From Baseline in Quality of Life Questionnaire for Bronchiectasis (QOL-B)-Respiratory Symptoms","Novartis Pharmaceuticals|Queen's University Belfast, UK|University Hospital Antwerp, BE|University of Milan, IT|Fundacion Clinic per a la Recerca Biomedica|Erasmus Medical Center|Papworth Hospital Cambridge, UK|Royal Brompton Hospital Trust, UK|University of Dundee|University of Edinburgh|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","107","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CTBM100G2202|2015-003040-39","February 8, 2017","March 20, 2019","March 20, 2019","March 18, 2016","August 14, 2020","August 25, 2020","Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Nice, Cedex1, France|Novartis Investigative Site, Montpellier cedex 5, Herault, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Essen, North Rhine-Westphalia, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pordenone, PN, Italy|Novartis Investigative Site, Milan, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Scafati, Italy|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunitat Valencia, Spain|Novartis Investigative Site, Baracaldo - Vizcaya, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Valladolid, Spain|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom|Novartis Investigative Site, Dundee, Perthshire, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Lancaster, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02712983/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02712983/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02712983"
11,"NCT04643587","Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)",,"Recruiting","No Results Available","Noncystic Fibrosis Bronchiectasis (NCFB)","Biological: CSL787|Drug: Placebo","Number of subjects with treatment emergent adverse events (TEAEs) - overall, severity and causality|Percent of subjects with TEAEs - overall, severity and causality|Maximum concentration (Cmax) of CSL787 in sputum and serum in healthy subjects|Time of maximum concentration (Tmax) of CSL787 in sputum and serum in healthy subjects|Area under the concentration-time curve from time 0 to 24 hours (AUC0-24h) of CSL787 in sputum and serum in healthy subjects|Area under the concentration-time curve from time 0 to last quantifiable time point (AUC0-last) of CSL787 in sputum and serum in healthy subjects|Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) of CSL787 in sputum and serum in healthy subjects|Apparent total clearance of the drug (CL/F) of CSL787 in sputum and serum in healthy subjects|Apparent volume of distribution during the elimination phase (V/F) of CSL787 in sputum and serum in healthy subjects|Terminal elimination half-life (T1/2) of CSL787 in sputum and serum in healthy subjects|Cmax of CSL787 in sputum and serum of NCFB subjects|Tmax of CSL787 in sputum and serum of NCFB subjects|Ctrough of CSL787 in sputum and serum of NCFB subjects|AUCtau of CSL787 in sputum and serum of NCFB subjects|T1/2 of CSL787 in sputum and serum of NCFB subjects|CL/F of CSL787 in sputum and serum of NCFB subjects|V/F of CSL787 in sputum and serum of NCFB subjects|Accumulation Ratio (AR) for Cmax of CSL787 in sputum and serum of NCFB subjects|AR for Ctrough of CSL787 in sputum and serum of NCFB subjects|AR for AUCtau of CSL787 in sputum and serum of NCFB subjects","CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CSL787_1001|2020-002684-66","December 7, 2020","November 2022","November 2022","November 25, 2020",,"June 10, 2022","Medicines Evaluation Unit (MEU), Manchester, England, United Kingdom|Celerion, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04643587"
12,"NCT00889967","Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis ""ORBIT-1""",,"Completed","No Results Available","Non-Cystic Fibrosis Bronchiectasis","Drug: Ciprofloxacin for Inhalation|Drug: Placebo","The primary efficacy endpoint is defined as the mean change in P. aeruginosa density in sputum (log10) CFU/gram of sputum from Baseline to Day 28.|Microbiological efficacy|Time to, number of, severity of, and time to resolve exacerbations|Changes in spirometry 4. Quality of life (QOL) 5. Safety and tolerability|Quality of life (QOL)|Safety and tolerability","Aradigm Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARD-3100-0901","February 2010","April 2011","June 2011","April 29, 2009",,"January 25, 2017","Phoenix, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|Torrance, California, United States|Waterbury, Connecticut, United States|Brandon, Florida, United States|Miami, Florida, United States|Council Bluffs, Iowa, United States|Summit, New Jersey, United States|New York, New York, United States|Elizabeth City, North Carolina, United States|Toledo, Ohio, United States|Philadelphia, Pennsylvania, United States|McKinney, Texas, United States|Calgary, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Montreal, Quebec, Canada|St. Jerome, Quebec, Canada|Berlin, Germany|Donaustauf, Germany|Heidelberg, Germany|Neuwied, Germany|""Ground Floor, Tower Block, Lisburn Road, Belfast, Britain, United Kingdom|""1st Floor, Nuffield House, B15 2TH, Birmingham, Britain, United Kingdom|""Duckworth Lane,, Bradford, Britain, United Kingdom|""Southmoor Road, M23 9LT, Manchester, Britain, United Kingdom|Newcastle upon Tyne, Freeman Road, High Heaton, United Kingdom|London, High Street Lewisham, United Kingdom|""Bordesley Green East, Birmingham, United Kingdom|""133 Balornock Road, Glasgow, United Kingdom|Royal Brompton Hospital, London, United Kingdom|""Stott Lane, Salford, United Kingdom|""Newcastle Road, Stoke on Trent, United Kingdom|""Northumbria Healthcare, Tyne and Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00889967"
13,"NCT02531984","The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis","AZI-STOP","Unknown status","No Results Available","Non Cystic Fibrosis Bronchiectasis in Children","Drug: Azithromycin","Time of onset of the first respiratory exacerbation in the two groups of patients: those who continued treatment with azithromycin and those who stopped the treatment","Assistance Publique Hopitaux De Marseille",,"3 Years to 17 Years   (Child)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-26|RC12_3643","August 2015","August 2017","August 2018","August 25, 2015",,"August 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02531984"
14,"NCT02104245","Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)",,"Completed","No Results Available","Non Cystic Fibrosis Bronchiectasis","Drug: Ciprofloxacin dispersion for inhalation|Drug: Placebo","Time to first pulmonary exacerbation (from baseline)","Aradigm Corporation|Grifols Therapeutics LLC|Savara Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARD-3150-1202","May 28, 2014","August 11, 2016","October 2016","April 4, 2014",,"March 26, 2021","Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Sacramento, California, United States|San Diego, California, United States|Torrance, California, United States|Danbury, Connecticut, United States|Miami, Florida, United States|Orlando, Florida, United States|Winter Park, Florida, United States|Decatur, Georgia, United States|Duluth, Georgia, United States|Port Huron, Michigan, United States|Omaha, Nebraska, United States|Lebanon, New Hampshire, United States|Summit, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Rock Hill, South Carolina, United States|Spartanburg, South Carolina, United States|Tyler, Texas, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Greenslopes, Queensland, Australia|Adelaide, South Australia, Australia|Nedlands, Western Australia, Australia|Perth, Western Australia, Australia|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Windsor, Ontario, Canada|St-Jerome, Quebec, Canada|Belgrade, Former Serbia and Montenegro|Knez Selo, Former Serbia and Montenegro|Kragujevac, Former Serbia and Montenegro|Sremska Kamenica, Former Serbia and Montenegro|Créteil Cedex 01, France|Grenoble cedex, France|Nice Cedex 1, France|Pessac Cedex, France|Rouen Cedex, France|Toulouse cedex 9, France|Kutaisi, Georgia|Tbilisi, Georgia|Budapest, Hungary|Nyiregyhaza, Hungary|Szekesfehervar, Hungary|Torokbalint, Hungary|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Tel-Aviv, Israel|Avellino, Italy|Napoli, Italy|Parma, Italy|Pisa, Italy|San Gerardo, Italy|Terni, Italy|Trieste, Italy|Suwon, Gyeonggi-do, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Otahuhu, Auckland, New Zealand|Hamilton, Waikato, New Zealand|Tauranga, New Zealand|Jesus Maria, Lima, Peru|La Victoria, Lima, Peru|Pueblo Libre, Lima, Peru|San Juan de Miraflores, Lima, Peru|Bialystok, Poland|Krakow, Poland|Ruda Slaska, Poland|Warsaw, Poland|Arad, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Iasi, Romania|Barcelona, Spain|La Coruna, Spain|Lleida, Spain|Valencia, Spain|Stockton-on-Trees, Cleveland, United Kingdom|Wigan, Greater Manchester, United Kingdom|Cambridge, United Kingdom|Colchester, United Kingdom|Cottingham, United Kingdom|Lancaster, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom|North Sheilds, United Kingdom|Southampton, United Kingdom|Telford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02104245"
15,"NCT01792440","The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Non-cystic Fibrosis Bronchiectasis|Healthy",,"Assess predictive value of sputum colour chart to evaluate airway inflammation|Link the degree of airway inflammation to the proteolytic activity of sputum enzymes.","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","B32220084152|B51060","September 2009","July 2010","December 2012","February 15, 2013",,"February 20, 2013","University Hospital Leuven, Leuven, Vlaams-Brabent, Belgium",,"https://ClinicalTrials.gov/show/NCT01792440"
16,"NCT03218917","Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Non-Cystic Fibrosis Bronchiectasis","Drug: INS1007 10 mg oral tablet|Drug: INS1007 25 mg oral tablet|Drug: Placebo Oral Tablet","Time to first pulmonary exacerbation|Rate of pulmonary exacerbations|Change from Baseline in the Respiratory Symptoms Domain Score of the Quality of Life (QOL) Bronchiectasis questionnaire|Change from Screening in post-bronchodilator forced expiratory volume in 1 second (FEV1)|Change in concentration of active neutrophil elastase (NE) in sputum from pre-treatment to on treatment","Insmed Incorporated","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INS1007-201|2017-002533-32","December 1, 2017","December 12, 2019","December 12, 2019","July 17, 2017",,"December 14, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Phoenix Medical Group, Peoria, Arizona, United States|NewportNativeMD, Newport Beach, California, United States|Palmtree Clinical Research, Palm Springs, California, United States|UC Davis Medical Center, Sacramento, California, United States|Stanford University Medical Center, Stanford, California, United States|National Jewish Heath, Denver, Colorado, United States|UConn Health Center, Farmington, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Clinical Research Specialists, LLC, Celebration, Florida, United States|St. Francis Medical Institute, Clearwater, Florida, United States|University of Florida, Gainesville, Florida, United States|San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States|The Emory Clinic, Pulmonology, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|Johns Hopkins University, Division of Pulmonary and Critical Care Medicine, Baltimore, Maryland, United States|Pulmonary and Critical Care Associates of Baltimore, Towson, Maryland, United States|Mid Atlantic Pulmonary & Research Center, Westminster, Maryland, United States|Michigan Medicine, Ann Arbor, Michigan, United States|NYU Pulmonary & Critical Care Associates, New York, New York, United States|Columbia University Medical Center/ New York Presbyterian Hospital, New York, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Novant Health Pulmonary Medicine South, Charlotte, North Carolina, United States|Southeastern Research Center, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|SMS Clinical Research, LLC, Mesquite, Texas, United States|The University of Texas Health Science at Tyler, Tyler, Texas, United States|MultiCare Institute for Research & Innovation, Tacoma, Washington, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Mater Misericordia Medical Centre, Brisbane, Queensland, Australia|Gallipoli Medical Research Foundation, Brisbane, Queensland, Australia|Metro North Hospital and Health Service (The Prince Charles Hospital), Chermside, Queensland, Australia|Respiratory Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia|Respiratory Clinical Trials PTY LTD, Kent Town, South Australia, Australia|Box Hill Hospital, Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Institute for Respiratory Health, Nedlands, Western Australia, Australia|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Medical Center ReSpiro Ltd (Kiselov), Razgrad, Momina, Bulgaria|Medical Center UNIMED, Plovdiv, Bulgaria|MHAT ""Dr IvanSeliminski""-Sliven, Sliven, Bulgaria|Cardioart Medical Center, Stara Zagora, Bulgaria|Hvidovre Hospital, Hvidovre, Capital Region, Denmark|Aarhus University Hospital, Aarhus, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Krankenhaus Donaustauf, Donaustauf, Bavaria, Germany|Klinikum der Universität München Medizinische Klinik V Pneumologie / Mukoviszidose-Zentrum für Erwachsene, Munich, Bavaria, Germany|Klinikum Nuernberg, Nuernberg, Bayern, Germany|Universitätsklinikum Frankfurt, Frankfurt, Hessen, Germany|IKF Pneumologie Frankfurt, Frankfurt, Hessen, Germany|Ruhrlandklinik Essen, University Essen, Essen, NRW, Germany|Forschungszentrum Borstel, Borstel, Schleswig-Holstein, Germany|Universitätsklinikum Jena, Jena, Thuringen, Germany|Research Center for Medical Studies (RCMS), Berlin, Germany|Städt. Klinikum München GmbH, Bogenhausen, München, Germany|University of Milan, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardia, Italy|Ospedale San Gerardo, Monza, Monza E Brianza, Italy|University Hospital of Pisa, Pisa, Via Paradisa 2, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|ICS Maugeri spa SB, IRCSS Telese, Telese Terme, Italy|Inha University Hospital, Incheon, Jung-gu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Namdong-gu, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|The Catholic University of Korea Incheon St. Mary's Hospital, Incheon, Korea, Republic of|The Catholic University of Korea, St. Paul's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Noordwest Ziekenhuis Group, Alkmaar, Netherlands|Amphia Longresearch Astma/COPD Uni 52/5e etage, Breda, Netherlands|RadboudUMC, location Dekkerswald, Nijmegen, Netherlands|Zuyderland MC, Sittard, Netherlands|P3 Research, Tauranga, BOP, New Zealand|P3 Research (Hawke's Bay), Hastings, Hawkes Bay, New Zealand|Southern District health Board/Dunedin Hospital, Dunedin, Otago, New Zealand|Waikato District Health Board, Hamilton, Waikato, New Zealand|Auckland District Health Board, Greenlane clinical Centre, Auckland, New Zealand|Centrum Badan Klinicznych, Piotr Napora Lekarze i Spolka Partnerska, Osrodek Badan Wczesnej Fazy, Wrocław, Dolnośląskie, Poland|Grażyna Jasieniak Pinis Niepubliczny Zakład Opieki Zdrowotnej Atopia, Kraków, Poland|NZOZ Krak-Medyk Sp. z o.o, Kraków, Poland|Gabinet Lekarski Pediatryczno-Alergologiczny Zenon Bukowczan, Sucha Beskidzka, Poland|Medical University of Lodz Poland, Łódź, Poland|Singapore General Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain|Hospital Universiatrio y politecnico La Fe, Valencia, Spain|NHS Tayside, Dundee, Angus, United Kingdom|Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom|Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, Lancashire, United Kingdom|Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, Merseyside, United Kingdom|NHS Lothian, Edinburgh, Scotland, United Kingdom|Ashford and St Peter's Hospitals NHS Foundation Trust, Chertsey, Surrey, United Kingdom|The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom|Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03218917"
17,"NCT04322929","Roflumilast in Non-CF Bronchiectasis Study (2019)",,"Recruiting","No Results Available","Non-cystic Fibrosis Bronchiectasis","Drug: Roflumilast Oral Tablet","24-hour sputum volume|Sputum leukocyte density|Sputum pro-inflammatory cytokines (IL-1β, IL-8, TNF-alpha, and IL-17) and LTB4|Sputum neutrophil elastase|Sputum bacterial colonization and load|Health-related quality of life (HRQoL)","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROF2019_v2","November 12, 2020","February 28, 2022","June 30, 2022","March 26, 2020",,"April 28, 2021","Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04322929"
18,"NCT03428334","Roflumilast in Non-CF Bronchiectasis Study",,"Completed","No Results Available","Non-cystic Fibrosis Bronchiectasis","Drug: Oral roflumilast","sputum leukocyte density","The University of Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROF2017_v1","May 10, 2018","August 31, 2019","August 31, 2019","February 9, 2018",,"October 1, 2019","Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03428334"
19,"NCT03093974","Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection.","PROMIS-I","Completed","No Results Available","Non Cystic Fibrosis Bronchiectasis","Drug: Colistimethate Sodium|Drug: Saline Solution","Annualized Pulmonary Exacerbation rate|Time to first pulmonary exacerbation|Annualised number of pulmonary exacerbation-free days|Number of severe NCFB pulmonary exacerbations,|Time to first severe pulmonary exacerbation|Quality of life (SGRQ)|Quality of Life (QOL-B)|Days of work absence|P. aeruginosa density","Zambon SpA","All","18 Years and older   (Adult, Older Adult)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Z7224L01","June 6, 2017","April 9, 2021","April 9, 2021","March 28, 2017",,"August 10, 2021","Zambon Investigative Site, Adelaide, Australia|Zambon Investigative Site, Adelaide, Australia|Zambon Investigative Site, Chermside, Australia|Zambon Investigative Site, Concord, Australia|Zambon Investigative Site, Frankston, Australia|Zambon Investigative Site, Greenslopes, Australia|Zambon Investigative Site, Melbourne, Australia|Zambon Investigative Site, Nedlands, Australia|Zambon Investigative Site, New Lambton Heights, Australia|Zambon Investigative Site, South Brisbane, Australia|Zambon Investigative Site, Spearwood, Australia|Zambon Investigative Site, Westmead, Australia|Zambon Investigative Site, Gent, Belgium|Zambon Investigative Site, Roeselare, Belgium|Zambon Investigative Site, Berlin, Germany|Zambon Investigative Site, Berlin, Germany|Zambon Investigative Site, Essen, Germany|Zambon Investigative Site, Frankfurt am Main, Germany|Zambon Investigative Site, Frankfurt am Main, Germany|Zambon Investigative Site, Hamburg, Germany|Zambon Investigative Site, Hannover, Germany|Zambon Investigative Site, Lübeck, Germany|Zambon Investigative Site, Muenchen, Germany|Zambon Investigative Site, München, Germany|Zambon Investigative Site, Münster, Germany|Zambon Investigative Site, Athens, Greece|Zambon Investigative Site, Haifa, Israel|Zambon Investigative Site, Jerusalem, Israel|Zambon Investigative Site, Kfar Saba, Israel|Zambon Investigative Site, Petah Tikva, Israel|Zambon Investigative Site, Reẖovot, Israel|Zambon Investigative Site, Tsrifin, Israel|Zambon Investigative Site, Orbassano, TO, Italy|Zambon Investigative Site, Bari, Italy|Zambon Investigative Site, Brescia, Italy|Zambon Investigative Site, Foggia, Italy|Zambon Investigative Site, Milano, Italy|Zambon Investigative Site, Monza, Italy|Zambon Investigative Site, Palermo, Italy|Zambon Investigative Site, Palermo, Italy|Zambon Investigative Site, Pavia, Italy|Zambon Investigative Site, Pisa, Italy|Zambon Investigative Site, Roma, Italy|Zambon Investigative Site, Groningen, Netherlands|Zambon Investigative Site, Auckland, New Zealand|Zambon Investigative Site, Auckland, New Zealand|Zambon Investigative Site, Christchurch, New Zealand|Zambon Investigative Site, Dunedin, New Zealand|Zambon Investigative Site, Hamilton West, New Zealand|Zambon Investigative Site, Aveiro, Portugal|Zambon Investigative Site, Braga, Portugal|ZambonInvestigative Site, Coimbra, Portugal|Zambon Investigative Site, Guimarães, Portugal|Zambon Investigative site, Lisboa, Portugal|Zambon Investigative Site, Loures, Portugal|Zambon Investigative Site, Porto, Portugal|Zambon Investigative Site, Porto, Portugal|Zambon Investigative Site, Vila Nova De Gaia, Portugal|Zambon Investigative Site, A Coruña, Spain|Zambon Investigative Site, Barcelona, Spain|Zambon Investigative Site, Barcelona, Spain|Zambon Investigative Site, Barcelona, Spain|Zambon Investigative Site, Lleida, Spain|Zambon Investigative Site, Madrid, Spain|Zambon Investigative Site, Madrid, Spain|Zambon Investigative Site, Santander, Spain|Zambon Investigative Site, Sevilla, Spain|Zambon Investigative Site, Torrejón de Ardoz, Spain|Zambon Investigative Site, Usansolo, Spain|Zambon Investigative Site, Valencia, Spain|Zambon Investigative Site, Valencia, Spain|Zambon Investigative Site, Saint Gallen, Switzerland|Zambon Investigative Site, Cambridge, United Kingdom|Zambon Investigative Site, Cardiff, United Kingdom|Zambon Investigative site, Dundee, United Kingdom|Zambon Investigative Site, Edinburgh, United Kingdom|Zambon Investigative Site, Gillingham, United Kingdom|Zambon Investigative Site, Glasgow, United Kingdom|Zambon Investigative Site, Kirkcaldy, United Kingdom|Zambon Investigational site, Liverpool, United Kingdom|Zambon Investigative Site, Llanelli, United Kingdom|Zambon Investigative Site, London, United Kingdom|Zambon investigative Site, Manchester, United Kingdom|Zambon Investigative Site, Newcastle upon Tyne, United Kingdom|Zambon Investigative Site, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03093974"
20,"NCT01515007","Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)",,"Completed","No Results Available","Non Cystic Fibrosis Bronchiectasis","Drug: Ciprofloxacin dispersion for inhalation|Drug: Placebo","Time to first exacerbation|Number of exacerbations","Aradigm Corporation|Grifols Therapeutics LLC|Savara Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARD-3150-1201","March 31, 2014","August 17, 2016","October 2016","January 23, 2012",,"March 26, 2021","Peoria, Arizona, United States|Phoenix, Arizona, United States|Downey, California, United States|Los Angeles, California, United States|Poway, California, United States|Farmington, Connecticut, United States|Washington, District of Columbia, United States|Celebration, Florida, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Sebring, Florida, United States|Kailua, Hawaii, United States|Chicago, Illinois, United States|Columbia, Maryland, United States|Royal Oak, Michigan, United States|Rochester, Minnesota, United States|Lincoln, Nebraska, United States|Cedar Knolls, New Jersey, United States|New Hyde Park, New York, United States|New York, New York, United States|Syracuse, New York, United States|Charlotte, North Carolina, United States|Huntersville, North Carolina, United States|Oklahoma City, Oklahoma, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Fort Worth, Texas, United States|Tyler, Texas, United States|Falls Church, Virginia, United States|Concord, New South Wales, Australia|Westmead, New South Wales, Australia|Brisbane, Queensland, Australia|Cairns, Queensland, Australia|South Brisbane, Queensland, Australia|Daw Park, South Australia, Australia|Footscray, Victoria, Australia|Heidelberg, Victoria, Australia|Adelaide, Australia|Calgary, Alberta, Canada|Kelowna, British Columbia, Canada|Montreal, Quebec, Canada|Borstel, Schleswig-Holstein, Germany|Berlin, Germany|Donaustaff, Germany|Freiburg, Germany|Hannover, Germany|Immenstadt im Allgau, Germany|Lubeck, Germany|Munich, Germany|Budapest, Hungary|Debrecen, Hungary|Miskolc, Hungary|Szombathely, Hungary|Dublin, Ireland|Galway, Ireland|Ashkelon, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Rehovot, Israel|Tel Aviv, Israel|Pavia, PV, Italy|Acquaviva delle Fonti, Italy|Bologna, Italy|Ferrara, Italy|Firenze, Italy|Milano, Italy|Pisa, Italy|Busan, Korea, Republic of|Seoul, Korea, Republic of|Cekule, Latvia|Daugavpils, Latvia|Liepaja, Latvia|Riga, Latvia|Bialystok, Poland|Chrzanow, Poland|Warsaw, Poland|Wroclaw, Poland|Bucuresti, Romania|Constanta, Romania|Timisoara, Romania|Durban, KwaZulu-Natal, South Africa|Pietermaritzburg, KwaZulu-Natal, South Africa|Amanzimtoti, South Africa|Cape Town, South Africa|Krugersdorp, South Africa|Palma de Mallorca, Islas Baleares, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Malaga, Spain|Kaohsiung, Taiwan|Taichung City, Taiwan|Taipei City, Taiwan|Glasgow, Scotland, United Kingdom|Birmingham, West Midlands, United Kingdom|Bradford, United Kingdom|Dundee, United Kingdom|Liverpool, United Kingdom|Llandough, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle upon Tyne, United Kingdom|Nottinghamshire, United Kingdom|Stoke-on-Trent, United Kingdom|Tyne And Wear, United Kingdom|Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01515007"
21,"NCT05369624","Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program",,"Completed","No Results Available","Non-cystic Fibrosis Bronchiectasis|Pulmonary Rehabilitation","Other: Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)","Exercise capacity of Non-cystic Fibrosis Bronchiectasis ( Non-CF bronchiectasis) after pulmonary rehabilitation home-based program (PRHP). Change in VO2 (oxygen consumption, ml/min)|Level of physical activity (METS) of Non-CF bronchiectasis and its changes after PRHP|Impact of quality of life before and after PRHP|Dyspnoea|Exacerbations|Level of physical activity (number of steps) of Non-CF bronchiectasis and its changes after PRHP","Hospital Universitario Virgen Macarena","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","SCHNR15","May 8, 2018","March 14, 2019","March 14, 2020","May 11, 2022",,"May 18, 2022","Virginia Almadana Pacheco, Seville, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT05369624/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT05369624/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT05369624"
22,"NCT04010799","A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis",,"Completed","No Results Available","Cystic Fibrosis|Non-Cystic Fibrosis Bronchiectasis","Drug: CHF 6333|Drug: Placebo","Adverse event|Change in Vital signs|Heart Rate|PR interval|QRS interval|QTCf interval|FEV1|AUC|Cmax|T max|C24h|Rac|NE activity","Chiesi Farmaceutici S.p.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLI-06333AA1-16|2018-002508-15","May 27, 2019","March 8, 2021","March 8, 2021","July 8, 2019",,"March 30, 2021","IKF Institut für klinische Forschung Pneumologie, Frankfurt/Main, Germany",,"https://ClinicalTrials.gov/show/NCT04010799"
23,"NCT01906047","Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis",,"Death","Universitaire Ziekenhuizen Leuven","All","18 Years to 65 Years   (Adult, Older Adult)",,"189","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NCFB chronic pollution","June 2006","October 2012","April 2013","July 23, 2013",,"July 23, 2013","UZ Leuven, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT01906047"
24,"NCT02614300","The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis",,"Unknown status","No Results Available","Non-cystic Fibrosis Bronchiectasis","Other: Pulmonary Rehabilitation and Chest Physiotherapy|Other: Pulmonary Rehabilitation|Other: Chest Physiotherapy","Change from Baseline Exercise tolerance capacity measured as the distance walked in meters during the shuttle test at constant speed (ESWT) at 12 weeks.|Exacerbations incidence and symptoms|Change from Baseline Health related quality of life at 12 weeks.|Change from Baseline Impact of expectoration on the quality of life at 12 weeks.|Sputum colour|Change from Baseline FEV1, FVC and FEV1/FVC at 12 weeks.|Change from Baseline Physical activity level measured by accelerometry at 12 weeks.|Sputum quantity","Hospital Clinic of Barcelona|Sociedad Española de Neumología y Cirugía Torácica","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","PulmRehab_NCFBE","November 2015","December 2017",,"November 25, 2015",,"November 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02614300"
25,"NCT02088216","Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis","BENE","Completed","Has Results","Non-Cystic Fibrosis Bronchiectasis","Drug: N-acetylcysteine|Other: On-demand treatment","Median Number of Exacerbations|Change of Volume of Sputum From Baseline Parameters After the 12-month Follow-up.|Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa|Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores From Baselines|Change in Percentage of Predicted Forced Expiratory Volume in One Second (FEV1%) From Baselines|Change of Forced Expiratory Volume in One Second (FEV1) (L) From Baselines|Change of Forced Vital Capacity (FVC) From Baselines|Time to the First Exacerbation|Time to Recurrent Exacerbations|Nature of Sputum (Number of Patients With Yellow Purulent)|Adverse Events (AEs) (Elevation of Liver Enzymes)","Qilu Hospital of Shandong University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCFB-FLS-01","April 1, 2014","December 1, 2017","March 30, 2018","March 14, 2014","February 18, 2019","March 14, 2019","Qilu Hospital of Shandong University, Jinan, Shandong, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02088216/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02088216/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02088216"
26,"NCT02096315","Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.",,"Terminated","No Results Available","Bronchiectasis|Lower Respiratory Infection","Drug: POL7080","Sputum bacterial clearance|Adverse events|Laboratory abnormalities.|Volume of sputum in 24 hours","Polyphor Ltd.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POL7080-002","December 2013","November 2015","November 2015","March 26, 2014",,"February 1, 2017","Hospital Bellvitge, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital La Fe, Valencia, Spain|Royal Infirmary, City of Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02096315"
27,"NCT01854788","3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Other: Autogenic drainage|Other: Slow expiration with glottis opened in lateral posture|Other: Temporary-positive expiratory pressure","Weight of sputum expectorated during each airway clearance therapy session|Weight of sputum expectorated 24 hours post each bronchial session|Saint George Respiratory Questionnaire (SGRQ)|Leicester Cough Questionnaire (LCQ)","Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Uniko2010.01","September 2010","June 2012","August 2012","May 16, 2013",,"May 16, 2013","Hospital CLinic, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01854788"
28,"NCT00868075","Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Procedure: Chest physiotherapy|Procedure: Chest Physiotherapy + Exercise Program","The primary endpoint of this study is improvement in exercise tolerance from an incremental walk test.|These include pulmonary physiology, 24 hour sputum volume, sputum appearance, health related quality of life and systemic inflammation.","NHS Lothian","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","08/S1102/40","March 2009","August 2011","August 2011","March 24, 2009",,"November 8, 2011","Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00868075"
29,"NCT03147651","Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis",,"Unknown status","No Results Available","Bronchiectasis",,"Oxygen Uptake (VO2)|Spirometry|Oxygen saturation|Minute ventilation (VE)|carbon dioxide production (VCO2)","Rambam Health Care Campus","All","7 Years and older   (Child, Adult, Older Adult)",,"119","Other","Observational","Observational Model: Cohort|Time Perspective: Other","0048-15-RMB-CTIL","October 2015","September 2017","December 2017","May 10, 2017",,"May 10, 2017","RAMBAM Health Care Campus, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT03147651"
30,"NCT04090294","Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis",,"Unknown status","No Results Available","Bronchiectasis","Drug: Roflumilast","Assessment of efficacy of Roflumlilast regarding control of patients with non cystic fibrosis bronchiectasis|Assessment of efficacy of roflumlilast in change of performance in patients with non cystic fibrosis bronchiectasis|Assessment of efficacy of roflumlilast on change in Pulmonary function in patients with non cystic fibrosis bronchiectasis|Assessment of efficacy of roflumlilast on change of symptoms in patients with non cystic fibrosis bronchiectasis|Assessment of efficancy of roflumlilast on change in systemic inflammation in patients with non cystic fibrosis bronchiectasis","Assiut University","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","35","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Roflumilast in bronchiectasis","October 1, 2019","September 2020","November 2020","September 16, 2019",,"October 3, 2019",,,"https://ClinicalTrials.gov/show/NCT04090294"
31,"NCT04538859","A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong",,"Recruiting","No Results Available","Bronchiectasis Adult",,"Number of bronchiectasis exacerbation|Mortality rate","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ProBronchiectasis/2019","August 30, 2020","August 29, 2027","August 29, 2027","September 4, 2020",,"September 4, 2020","Chinese University of Hong, Hong Kong, Please Select, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04538859"
32,"NCT04658277","Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations",,"Recruiting","No Results Available","Bronchiectasis Adult","Drug: Clarithromycin|Other: Usual care","number of infectious exacerbations|Time to first exacerbation (Days)|Rate of symptom-based exacerbations (number of events per month)|change of post bronchodilator Forced Expiratory volume in 1 sec and forced vital capacity|change of exercise capacity (flights of stairs)|change of St George Respiratory Questionnaire Score|change of concentration of serum c-reactive protein (mg/L)","Chinese University of Hong Kong","All","50 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Macrolid/Bronchiectasis/2019","October 1, 2020","September 30, 2023","September 30, 2023","December 8, 2020",,"October 29, 2021","Chinese University of Hong, Hong Kong, Please Select, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04658277"
33,"NCT02324855","Long-term Airway Clearance Therapy in Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Other: Chest physiotherapy plus usual care","Cough severity (Auto-administered questionnaire: Leicester Cough Questionnaire)|Quality of life (Quality of life-Bronchiectasis questionnaire)|Exacerbation frequency|Exercise capacity (Incremental field test: shuttle test)|Lung function|Airway inflammation as assessed by spontaneous sputum analysis","Universidad San Jorge|Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Exacerb_BQnoFQ","October 2015","June 2020","June 2020","December 24, 2014",,"May 18, 2021","Universidad San Jorge, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02324855"
34,"NCT02782312","Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: ICS+LABA|Other: routine therapy","Quality of life|pulmonary function text|short-acting β2-adrenergic agonist (SABA) used|Exacerbations|sputum microorganism culture|Number of patients with adverse events","Shanghai Pulmonary Hospital, Shanghai, China","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110505","June 2011","June 2012","June 2013","May 25, 2016",,"May 26, 2016","Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02782312"
35,"NCT04122547","Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Exacerbation Copd|Bronchiectasis|Lung Function Decreased","Drug: Roflumilast|Drug: Placebo","acute deterioration of of bronchiectasis symptoms|Lung functions|Exercise capacity","Prince of Songkla University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","25132558","January 2015","December 2015","December 2015","October 10, 2019",,"October 10, 2019","Songklanagarind hospital, Songkhla, Thailand",,"https://ClinicalTrials.gov/show/NCT04122547"
36,"NCT02392663","Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Other: Hypertonic saline solution|Other: Hyaneb solution|Other: Isotonic saline solution","Wet sputum production|Impact on cough severity (Leicester Cough Questionnaire)|Lung function (Forced spirometry)|Safety and tolerability (Adverse events)","Hospital Clinic of Barcelona","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hyperosmolar_NCFB","March 2015","December 2015","January 2016","March 19, 2015",,"November 15, 2016","Hospital Clinic, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02392663"
37,"NCT02507843","Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis","VIDB","Unknown status","No Results Available","Bronchiectasis","Drug: Cholecalciferol|Drug: Placebo","Time to first acute exacerbation|total number of exacerbations per group|percentage of patients with one or more exacerbations per year|severity of diseases|using of antibiotics|quality of life","Shanghai Pulmonary Hospital, Shanghai, China","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150511","January 2015","December 2016","June 2017","July 24, 2015",,"July 24, 2015","Shanghai Pulmonary Hospital , Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02507843"
38,"NCT04170114","Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Cystic Fibrosis|Bronchiectasis","Other: Comprehensive Respiratory Physiotherapy","Forced Vital Capacity (FVC)|Forced Expiratory Volume in 1 second (FEV1)|Peak Expiratory Flow (PEF)|Respiratory Muscle Strength - MIP|Respiratory Muscle Strength - MEP|Six-minute walk test distance|M. Quadriceps strength","Bezmialem Vakif University","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","bvuhucgun02","January 1, 2020","November 1, 2020","November 1, 2020","November 20, 2019",,"November 3, 2020","Bezmialem Vakif Universitesi, Department of Physiotherapy and Rehabilitation, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04170114"
39,"NCT01801657","The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults",,"Unknown status","No Results Available","Bronchiectasis",,"The prevalence of respiratory virus infection in adults with bronchiectasis during a pulmonary exacerbation and when clinically stable.|The effect of respiratory virus infection on systemic and pulmonary inflammatory markers.|The effect of respiratory virus on lung function|The effect of respiratory virus infection on the bacterial load in bronchiectasis.|Time to recovery of respective symptom|The effect of respiratory virus on quality of life in patients with bronchiectasis|To investigate if upper respiratory tract symptoms are associated with viral infections.","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2009CB522109","February 2013","April 2014","April 2014","March 1, 2013",,"March 12, 2014","The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01801657"
40,"NCT02625246","Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis","CELEB","Completed","No Results Available","Bronchiectasis","Biological: hMSCs","Number of Participant with treatment emergent serious adverse events|Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum|rate of decline of lung function|frequency of acute exacerbations|reported dyspnea and quality of life assessment|death from any cause","Marilyn Glassberg|University of Miami","All","30 Years to 87 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150627","February 4, 2016","May 15, 2019","May 15, 2019","December 9, 2015",,"August 28, 2019","University of Miami Hospitals & Clinics, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02625246"
41,"NCT01299181","A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: Atorvastatin","The primary endpoint of this study is a reduction in cough at 6 months compared to baseline as measured by the Leicester Cough Questionnaire score.|pulmonary physiology and assessment of exercise capacity|24 hour sputum volume|qualitative and quantitative bacteriology|health related quality of life and health care utilisation|exacerbation frequency|safety of statin therapy|assessment of airways and systemic inflammation","University of Edinburgh|NHS Lothian","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2010-022040-20","November 2010","August 2013","August 2013","February 18, 2011",,"August 28, 2013","Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01299181"
42,"NCT02035488","Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: Tobramycin","Actual dose (dose minus remainder in inhaler after inhalation) of tobramycin|Area Under the plasma concentration versus time curve from 0 -12 hours (AUC0-12) of tobramycin •Area Under the plasma concentration versus time curve from 0 -12 hours (AUC0-12) of tobramycin|Maximum plasma concentration (Cmax ) of tobramycin|Time to maximum plasma concentration (Tmax) of tobramycin|Absorption rate constant (Ka) of tobramycin|Terminal elimination half-life (T1/2 el ) of tobramycin|Clearance following pulmonary administration (CL/F) (F= bioavailability) of tobramycin|Decrease of FEV1 in percentage measured by spirometry|Number of Participants with Adverse Events","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Tobra-02","October 2013","December 2014","December 2014","January 14, 2014",,"December 16, 2014","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT02035488"
43,"NCT00816309","Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?",,"Completed","No Results Available","Bronchiectasis","Device: Acapella Physiotherapy","24 hour sputum volume and assessment of cough severity (Leicester Cough Questionnaire)|spirometry (FEV1, FVC, FEF 25-75), incremental shuttle test, St George's Respiratory Questionnaire and Nottingham Health Profile NHP-2, quantitative bacteriology.","NHS Lothian","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AH003","October 2007","December 2008","March 2009","January 1, 2009",,"April 1, 2011","Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00816309"
44,"NCT02657473","Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis","BATTLE","Completed","No Results Available","Non-CF Bronchiectasis","Drug: tobramycin inhalation solution|Drug: Saline 0.9% inhalation solution","Number of exacerbations","Medical Center Alkmaar","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","54939","August 13, 2016","December 13, 2019","December 13, 2019","January 15, 2016",,"December 17, 2019","North West Clinics, Alkmaar, Noord-Holland, Netherlands|VU Medical Center, Amsterdam, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Canisius Ziekenhuis, Nijmegen, Netherlands|UMCU, Utrecht, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02657473/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02657473"
45,"NCT00930982","Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis",,"Completed","Has Results","Bronchiectasis","Drug: Ciprofloxacin (Cipro, BAYQ3939)|Drug: Placebo","Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29).|Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline in Forced Vital Capacity (FVC)|Time to Exacerbation With Antibiotic Intervention|Effect of Ciprofloxacin Inhale Treatment on Health-related Quality of Life (HRQoL) as Measured by the Saint George's Respiratory Questionnaire (SGRQ), Total Score|Effect of Ciprofloxacin Inhale Treatment on Health-related Quality of Life (HRQoL) as Measured by Chronic Respiratory Questionnaire - Self Administered Standardized (CRQ-SAS)|Change From Baseline in High Sensitive C-reactive Protein (hsCRP)|Change From Baseline in Absolute Neutrophil Count (ANC)|24-hour Sputum Volume|24-hour Sputum Color (Percentage of Participants With Non-clear Sputum)|Microbiological Response of Cipro Inhale Per Participant|Microbiological Response of Cipro Inhale Per Pathogen|Emergence of New Potential Respiratory Pathogens|Emergence of Resistance Among Baseline Pathogens","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12965|2009-009869-34","June 2009","September 2010","September 2010","July 2, 2009","January 30, 2012","December 12, 2014","Little Rock, Arkansas, United States|La Jolla, California, United States|Denver, Colorado, United States|Farmington, Connecticut, United States|Washington, District of Columbia, United States|Naples, Florida, United States|Michigan City, Indiana, United States|Mineola, New York, United States|Houston, Texas, United States|Tyler, Texas, United States|Payson, Utah, United States|Concord, New South Wales, Australia|South Brisbane, Queensland, Australia|Woollongabba, Queensland, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Heidelberg, Victoria, Australia|Prahran, Victoria, Australia|Nedlands, Western Australia, Australia|Löwenstein, Baden-Württemberg, Germany|Rüdersdorf, Brandenburg, Germany|Frankfurt, Hessen, Germany|Gelnhausen, Hessen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Witten, Nordrhein-Westfalen, Germany|Koblenz, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Geesthacht, Schleswig-Holstein, Germany|Großhansdorf, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Santiago de Compostela, A Coruña, Spain|Palma de Mallorca, Illes Baleares, Spain|Badajoz, Spain|Barcelona, Spain|Uppsala, Sweden|Bristol, Avon, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Liverpool, Merseyside, United Kingdom|Belfast, North Ireland, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Edinburgh, United Kingdom|Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00930982"
46,"NCT02106832","Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","RESPIRE 2","Completed","Has Results","Bronchiectasis","Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation|Drug: Placebo","Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo|Time to First Exacerbation Event Within 48 Weeks - Cipro 14 vs. Pooled Placebo|Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks|Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks|Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46)|Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46)|Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46)","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","521","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15626|2013-004659-19","April 30, 2014","September 13, 2016","October 19, 2016","April 8, 2014","September 1, 2017","October 2, 2017","Peoria, Arizona, United States|Fountain Valley, California, United States|La Jolla, California, United States|Long Beach, California, United States|Newport Beach, California, United States|San Diego, California, United States|Kissimmee, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Decatur, Georgia, United States|Skokie, Illinois, United States|Olathe, Kansas, United States|Rochester, Minnesota, United States|Brooklyn, New York, United States|Mineola, New York, United States|Asheville, North Carolina, United States|Portland, Oregon, United States|Doylestown, Pennsylvania, United States|Greenville, South Carolina, United States|Edinburg, Texas, United States|Tyler, Texas, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Capital Federal, Ciudad Auton. de Buenos Aires, Argentina|Godoy Cruz, Mendoza, Argentina|Córdoba, Argentina|Vicente López, Argentina|Kogarah, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Parkville, Victoria, Australia|Murdoch, Western Australia, Australia|Perth, Western Australia, Australia|Graz, Austria|Salzburg, Austria|Belo Horizonte, Minas Gerais, Brazil|Recife, Pernambuco, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Porto Alegre, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Gabrovo, Bulgaria|Kozloduy, Bulgaria|Lovech, Bulgaria|Razgrad, Bulgaria|Ruse, Bulgaria|Sevlievo, Bulgaria|Sliven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Fuzhou, Fujian, China|Guangzhou, Guangdong, China|Hohehot, Inner Mongolia, China|Suzhou, Jiangsu, China|Wuxi, Jiangsu, China|Nanchang, Jiangxi, China|Shenyang, Liaoning, China|Yinchuan, Ningxia, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Brno, Czechia|Prague 4, Czechia|Praha 2, Czechia|Praha 8, Czechia|Treuenbrietzen, Brandenburg, Germany|Frankfurt, Hessen, Germany|Neu-Isenburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Gelsenkirchen, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Bad Berka, Thüringen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Kowloon, Hong Kong|New Territories, Hong Kong|Shatin, Hong Kong|Daejeon, Daejeon Gwang''yeogsi, Korea, Republic of|Bucheon, Gyeonggido, Korea, Republic of|Incheon Gwangyeogsi,, Incheon Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Daugavpils, Latvia|Daugavpils, Latvia|Jurmala, Latvia|Kraslava, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Talsi, Latvia|Klaipeda, Lithuania|Vilnius, Lithuania|Alkmaar, Netherlands|Assen, Netherlands|Groningen, Netherlands|Helmond, Netherlands|Maastricht, Netherlands|Sittard-Geleen, Netherlands|Veldhoven, Netherlands|City of San Fernando, Philippines|Manila, Philippines|Manila, Philippines|Quezon City, Philippines|Quezon City, Philippines|Bielsko-Biala, Poland|Czestochowa, Poland|Gorzow Wielkopolski, Poland|Grudziadz, Poland|Katowice, Poland|Kielce, Poland|Kielce, Poland|Kielce, Poland|Krakow, Poland|Ksawerow, Poland|Mrozy, Poland|Ostrowiec Swietokrzyski, Poland|Rzeszow, Poland|Warszawa, Poland|Vila Nova de Gaia, Porto, Portugal|Angra do Heroísmo, Região Autónoma dos Açores, Portugal|Faro, Portugal|Lisboa, Portugal|Lisboa, Portugal|Bragadiru, Romania|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Codlea, Romania|Constanta, Romania|Iasi, Romania|Ploiesti, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ufa, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Belgrade, Serbia|Cacak, Serbia|Knez Selo, Serbia|Kragujevac, Serbia|Sombor, Serbia|Sremska Kamenica, Serbia|Valjevo, Serbia|Bratislava, Slovakia|Presov, Slovakia|Johannesburg, Gauteng, South Africa|Amanzimtoti, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Chiayi, Taiwan|Kaohsiung, Taiwan|New Taipei City,, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand|Khon Kaen, Thailand|NakhonRatchasima, Thailand|Phitsanulok, Thailand|Udonthani, Thailand|Ankara, Turkey|Ankara, Turkey|Balcali, Turkey|Izmir, Turkey|Kampus, Turkey|Konya, Turkey|Maltepe, Turkey|Mersin, Turkey|Pendik, Turkey|Samsun, Turkey|Sehitkamil, Turkey",,"https://ClinicalTrials.gov/show/NCT02106832"
47,"NCT00484263","The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: Hypertonic saline 6% -","Number of pulmonary exacerbations|- St George Respiratory questionnaire - Leicester Cough Questionnaire - Lung Function Tests","The Alfred","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T10716","December 2007","October 2009","October 2009","June 8, 2007",,"June 23, 2011","The Alfred Hospital, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00484263"
48,"NCT01764841","Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","RESPIRE 1","Completed","Has Results","Bronchiectasis","Drug: Ciprofloxacin DPI (BAYQ3939)|Drug: Placebo","Time to First Exacerbation Event Within 48 Weeks|Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks|Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks|Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46)|Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46)|Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46)|Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46)","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","416","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15625|2011-004208-39","May 2, 2013","March 9, 2016","March 9, 2016","January 10, 2013","May 24, 2017","January 24, 2018","Jasper, Alabama, United States|Flagstaff, Arizona, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Fort Smith, Arkansas, United States|Los Angeles, California, United States|Torrance, California, United States|Ventura, California, United States|Farmington, Connecticut, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Celebration, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Weston, Florida, United States|Winter Park, Florida, United States|Lawrenceville, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Michigan City, Indiana, United States|Hazard, Kentucky, United States|Chesterfield, Missouri, United States|Summit, New Jersey, United States|New Hyde Park, New York, United States|New York, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Kingwood, Texas, United States|McKinney, Texas, United States|Tyler, Texas, United States|Abingdon, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Godoy Cruz, Mendoza, Argentina|Vicente López, Argentina|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Woodville, South Australia, Australia|Parkville, Victoria, Australia|Prahran, Victoria, Australia|Murdoch, Western Australia, Australia|Box Hill, Australia|Cairns, Australia|Frankston, Australia|Kogarah, Australia|Toorak Gardens, Australia|Aarhus C, Denmark|Hellerup, Denmark|Naestved, Denmark|Roskilde, Denmark|Clermont Ferrand, France|Montpellier, France|Nimes, France|Toulon, France|Heidelberg, Baden-Württemberg, Germany|Cottbus, Brandenburg, Germany|Frankfurt, Hessen, Germany|Neu-Isenburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Koblenz, Rheinland-Pfalz, Germany|Geesthacht, Schleswig-Holstein, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Benevento, Campania, Italy|Trieste, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Varese, Lombardia, Italy|Bari, Puglia, Italy|Cagliari, Sardegna, Italy|Catania, Sicilia, Italy|Pisa, Toscana, Italy|Verona, Veneto, Italy|Toon, Ehime, Japan|Nakagun, Ibaraki, Japan|Koshi, Kumamoto, Japan|Matsusaka, Mie, Japan|Tsu, Mie, Japan|Sakai, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Kiyose, Tokyo, Japan|Mitaka, Tokyo, Japan|Fukuoka, Japan|Daugavpils, Latvia|Daugavpils, Latvia|Jurmala, Latvia|Kraslava, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Talsu, Latvia|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Dunedin, New Zealand|Hamilton, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Bratislava, Slovakia|Presov, Slovakia|Santiago de Compostela, A Coruña, Spain|Elda, Alicante, Spain|Oviedo, Asturias, Spain|Badalona, Barcelona, Spain|L'Hospitalet, Barcelona, Spain|Sant Boi de Llobregat, Barcelona, Spain|Terrassa, Barcelona, Spain|Pozuelo de Alarcón, Madrid, Spain|Barcelona, Spain|Barcelona, Spain|Cáceres, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pontevedra, Spain|Valencia, Spain|Valencia, Spain|Cambridge, Cambridgeshire, United Kingdom|Exeter, Devon, United Kingdom|Plymouth, Devon, United Kingdom|Torbay, Devon, United Kingdom|Dundee, Dundee City, United Kingdom|Belfast, North Ireland, United Kingdom|Shrewsbury, Shropshire, United Kingdom|Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Londonderry, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01764841"
49,"NCT03056326","A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects","CHF6333 FIH","Completed","No Results Available","Non-Cystic Fibrosis Bronchiectasis|Cystic Fibrosis","Drug: CHF6333 (Part 1 - SAD)|Drug: Placebo (Part 1 - SAD)|Drug: CHF6333 (Part 2 - MAD)|Drug: Placebo (Part 2 - MAD)","Adverse events|Change in Vital signs|Heart Rate|QTcF interval|PR interval|QRS interval|Holter recording abnormalities|FEV1|Clinical chemistry and haematology|Urinalysis|Area under the plasma concentration|Peak plasma concentration (Cmax)|Time to reach the maximum plasma concentration (tmax)|Elimination half-life (t1/2)|Clearance (CL/F)|Volume of distribution (Vz/F)|Urinary excretion (Ae)|fraction excreted (fe)|Renal clearance (CLr)","Chiesi Farmaceutici S.p.A.","Male","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCD-06333AA1-01|2015-005552-94","November 2016","July 2017","July 2017","February 17, 2017",,"November 7, 2017","SGS Life Sciences, Antwerpen, Belgium",,"https://ClinicalTrials.gov/show/NCT03056326"
50,"NCT00728715","Efficacy of Budesonide-Formoterol in Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: budesonide-formoterol single inhaler|Drug: High dose of budesonide|Drug: A|Drug: B","Health related quality of life (measured by St Gorge Respiratory Questionnaire)|Forced spirometry; microbiological data, clinical data (dyspnea, cough, wheezes) and side effects","Hospital General de Requena|Esteve","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HGR-0000013","January 2004","January 2005","January 2005","August 6, 2008",,"August 6, 2008","Hospital General de Requena, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00728715"
51,"NCT02163642","Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis",,"Unknown status","No Results Available","Bronchiectasis","Device: Cyranose® 320","Change from baseline in sputum mucin levels at 12 months|Change from baseline in sputum mucin levels at 3 months|Change from baseline in sputum mucin levels at 6 months|Change from baseline in sputum mucin levels at 9 months","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Sociedad Española de Neumología y Cirugía Torácica","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IIBSP-BRO-2013-154","April 2014","April 2018","April 2018","June 13, 2014",,"September 8, 2016","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02163642"
52,"NCT02823587","Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis",,"Unknown status","No Results Available","Bronchiectasis","Other: Pulmonary Rehabilitation|Other: Control","Mucociliary transport in vivo|Mucociliary transport in vitro|Quality of Life in Bronchiectasis|Cough Impact Assessment|Health-Related Quality of Life|Impulse Oscillometry System (IOS)|Pulmonary Function Test|Six Minute Walking Test|Maximal Static Respiratory Pressures|Viscosity|Elasticity|Exhaled breath condensate|Exhaled Nitric Oxide Fraction (FeNO)|Cytokine Analysis TNF-α|Cytokine Analysis IL-6|Cytokine Analysis IL-10","University of Sao Paulo","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","USP 2016-1","July 2016","July 2018","December 2019","July 6, 2016",,"August 21, 2017","Ribeirão Preto Medical School, Ribeirão Preto, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02823587"
53,"NCT04017312","A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting",,"Unknown status","No Results Available","Bronchiectasis|Bronchiectasis With Acute Exacerbation","Device: High Frequency Chest Wall Oscillation|Device: Oscillating Positive Expiratory Pressure (OPEP)","Frequency of acute exacerbations of bronchiectasis|6-minute walk test|Pulmonary function tests|Quality of life measure using the Quality of Life - Bronchiectasis (QoL-B) tool|Time to first exacerbation|Number of exacerbation related hospitalizations|Number of exacerbation related inpatient hospital days|Number of exacerbation related ICU admissions|Number of exacerbation related ICU days|Number of exacerbation related outpatient visits (Physician's office, Urgent Care Visits, ED visits)|Number of courses of antibiotics during episodes of acute exacerbation|Number of antibiotic use days during episodes of acute exacerbation|Inflammation - measured by sputum neutrophil elastase level|Mean adherence to prescribed treatment regimen","Hill-Rom","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-RR-2019-001","August 23, 2019","November 2020","November 2020","July 12, 2019",,"February 17, 2020","NYU Langone Health, New York, New York, United States|Tennessee Comprehensive Lung and Sleep Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04017312"
54,"NCT01313624","Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis","AIR-BX1","Completed","Has Results","Bronchiectasis","Drug: AZLI|Drug: Placebo","Change in QOL-B Respiratory Symptoms Score at Day 28|Change in QOL-B Respiratory Symptoms Score at Day 84|Time to Protocol-Defined Exacerbation (PDE)","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","266","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-219-0101","April 2011","March 2013","June 2013","March 14, 2011","April 16, 2014","April 16, 2014","Pulmonary Associates, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, LTD, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center Heart and Lung Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Scottsdale, Arizona, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|UC Davis Medical Center Division of Pulmonary, Critical Care and Sleep Medicine, Sacramento, California, United States|Landon Pediatric Foundation, Ventura, California, United States|National Jewish Health, Denver, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Bay Area Chest Physicians, Clearwater, Florida, United States|University of Florida, Gainesville, Florida, United States|Pulmonary Disease Specialists (PDS) Research, Kissimmee, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Atlanta Pulmonary Group, Atlanta, Georgia, United States|Pulmonary and Critical Care Associates of Baltimore, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Cardio Pulmonary Research at St. Luke's Hospital, Chesterfield, Missouri, United States|Albany Medical Center, Albany, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Winthrop University Hospital - Clinical Trials Center, Mineola, New York, United States|St. Luke's Roosevelt Hospital, New York, New York, United States|University of Cincinnati / UC Health, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania Medical Center - Pulmonary, Allergy & Critical Care Division, Philadelphia, Pennsylvania, United States|Asthma Allergy & Pulmonary Associates, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Metroplex Pulmonary and Sleep Center, McKinney, Texas, United States|Alamo Clinical Research Associates, San Antonio, Texas, United States|University of Texas Health Science Center at Tyler, Tyler, Texas, United States|University of Virginia Pulmonary and Critical Care, Charlottesville, Virginia, United States|Inova Fairfax Hospital/ Heart and Vascular Institute Advanced Lung Disease and Transplant Center, Falls Church, Virginia, United States|Swedish Medical Center/Minor James Clinic, Seattle, Washington, United States|Multicare Pulmonary Specialist, Tacoma, Washington, United States|Concord Hospital, Concord, New South Wales, Australia|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Woolcock Institute of Medical Research, Glebe, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Royal Perth Hospital, Perth, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Mater Adult Hospital, Brisbane, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royla Adelaide Hospital, Adelaide, South Australia, Australia|Repatriation General Hospital, Daws Park, South Australia, Australia|Respiratory Clinical Trials, Toorak Gardens, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Peninsula Health, Frankston, Victoria, Australia|Alfred Hospital, Westmead, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Kelowna Respiratory and Allergy Clinic, Kelowna, British Columbia, Canada|The Lung Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital Pacific Lung Research, Vancouver, British Columbia, Canada|Kingston General Hospital / Queen's University, Kingston, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Dr. Anil Dhar Private Practice, Windsor, Ontario, Canada|Centre Hospitalier de L'Université de Montréal Hotel Dieu, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01313624"
55,"NCT01314716","Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis","AIR-BX2","Completed","Has Results","Bronchiectasis","Drug: AZLI|Drug: Placebo","Change in QOL-B Respiratory Symptoms Score at Day 28|Change in QOL-B Respiratory Symptoms Score at Day 84|Time to Protocol-Defined Exacerbation (PDE)","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-219-0104","April 2011","April 2013","July 2013","March 14, 2011","April 16, 2014","April 16, 2014","Florence Research Associates, Florence, Alabama, United States|Clinical Trials Connection, Flagstaff, Arizona, United States|Phoenix Medical Group, Peoria, Arizona, United States|Pulmonary Associates, Phoenix, Arizona, United States|AZ Pulmonary Specialists, LTD, Scottsdale, Arizona, United States|Pulmonary Consultants & Primary Care Physicians Medical Group, Inc., Orange, California, United States|UC San Diego Medical Center, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida, Jacksonville, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Sarasota Memorial Hospital - Clinical Research Center, Sarasota, Florida, United States|Pasadena Center for Medical Research, St. Petersburg, Florida, United States|Tampa General Hospital - New Lung Associates, Tampa, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Southeastern Lung Care PC, Decatur, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loess Hills Clinical Research, Council Bluffs, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Pulmonary & Critical Care Associates of Baltimore, Rosedale, Maryland, United States|Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Pulmonary & Allergy Associates, P.A., Summit, New Jersey, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Columbia University, NY Presbyterian Hospital, New York, New York, United States|UNC Chapel Hill, Chapel Hill, North Carolina, United States|The Oregon Clinic P.C./ Pulmonary Division, Portland, Oregon, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at Tyler, Tyler, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Pulmonary Consultants, PLLC, Tacoma, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Medical College of Wisconsin Froedtert Hospital, Milwaukee, Wisconsin, United States|Concord Hospital, Concord, New South Wales, Australia|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Royal Perth Hospital, Perth, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Repatriation General Hospital, Daw Park, South Australia, Australia|Burnside War Memorial Hospital Pharmacy, Toorak Gardens, South Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|CUB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|KUL UZ Gasthuisberg, Leuven, Belgium|Kelowna Respiratory Research and Allergy Clinic, Kelowna, British Columbia, Canada|The Lung Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|CHICAS - Centre Hospitalier Intercommunal des Alpes du sud, site de GAP, Gap, PACA, France|Service Activite Ambulatoire Pole Cardiovasculaire Hopital Nord, Marseille, France|CHU de Montpellier-Hopital Arnaud de Villeneuve, Montpellier Cedex 05, France|Hôpital Pasteur, CHU de Nice, Nice, France|Hopital Haut-Leveque, Pessac, France|CHU Toulouse - Hôpital Larrey, Toulouse, France|Research Center for Medical Studies (RCMS), Berlin-Charlottenburg (Westend), Germany|Charite Campus Virchow-Klinikum, Berlin, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|University Hospital Giessen, Giessen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Jena Clinic for Internal Medicine II, Jena, Germany|Univ.-Klinikum Leipzig, Innere Med., Leipzig, Germany|POIS Leipzig GbR, Leipzig, Germany|Klinikum Innenstadt der LMU Munchen, Munich, Germany|S.Anna Hospital, University of Ferrara, Ferrara, Italy|UO Broncopneumologia IRCCS Fondazione Cà Granda Milano, Milan, Italy|University of Modena and Reggio Emilia, Modena, Italy|Azienda Universitaria Federico II, Naples, Italy|Università di Pisa - Ospedale Cisanello, Pisa, Italy|Ospendale Civile Maggiore Centro Regionale Fibrosi Cistica, Verona, Italy|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Erasmus MC, Rotterdam, Netherlands|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital La Fe, Valencia, Spain|Papworth Hospital NHS Trust, Cambridgeshire, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Devon and Exeter Hospital, NHS Foundation Trust, Exeter, United Kingdom|Sir William Leech Centre for Lung Research, Freeman Hospital, Newcastle upon Tyne, United Kingdom|GBS RE Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Torbay District General Hospital, Torquay, Devon, United Kingdom|Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01314716"
56,"NCT03818646","Functional Respiratory Imaging in Bronchiectasis","FRIBE","Unknown status","No Results Available","Bronchiectasis","Diagnostic Test: Functional Respiratory Imaging","Airway volume|Airway resistance|Lung volume|Internal airflow distribution|Airway wall thickness|Blood vessel density|Centreline evaluation (airway dimensions over distance into the lung).|Lung function|QOL-B|LCQ|CRP","Papworth Hospital NHS Foundation Trust","All","18 Years to 80 Years   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P02470","January 2019","April 2019","April 2019","January 28, 2019",,"January 28, 2019","Royal Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03818646"
57,"NCT04509661","Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation",,"Not yet recruiting","No Results Available","Bronchiectasis Adult","Drug: LABA/LAMA or Placebo inhalation","Actue exacerbation|modified Medical Research Council score|Leicester Cough Questionnaire|Questionnaire of life-Bronchiectasis|FEV1, FVC|FEV1%|Incidence of atrial fibrillation|Incidence of coronary artery disease","Shanghai Pulmonary Hospital, Shanghai, China","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200413","September 1, 2020","June 1, 2024","June 1, 2024","August 12, 2020",,"August 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04509661"
58,"NCT03988816","Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Bronchiectasis",,"Unknown status","No Results Available","Bronchiectasis Adult","Drug: Roflumilast|Drug: Placebo oral tablet","Quality of life questionnaire|Other tools for quality of life|Dyspnea|Lung function|Adverse events","University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SDC 4706/18/057|2018/17035-5","December 6, 2019","December 2020","December 2020","June 17, 2019",,"January 13, 2020","Heart Institute (InCor) - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT03988816"
59,"NCT01463371","Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: Azithromycin","Changes in Nitric oxide,8-isoprostane, pH, nitrites (NO2) and nitrates(NO3) in exhaled breath condensate.|Number of Exacerbations|changes in lung function|colour and volume sputum,|Impact on functional capacity and health related quality of life|Changes in HRCT Lung scores","Instituto de Investigacion Sanitaria La Fe|Sociedad Valenciana de Neumología","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","04/2004/0144","October 2006","April 2007","September 2007","November 1, 2011",,"November 1, 2011","University Hospital La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01463371"
60,"NCT04884308","Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections",,"Recruiting","No Results Available","Cystic Fibrosis|Bronchiectasis Adult|Non-Tuberculous Mycobacteria","Biological: BCG TICE Vaccine","BCG Uptake","Johns Hopkins University|Cystic Fibrosis Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00256425","April 28, 2021","June 30, 2023","June 30, 2023","May 12, 2021",,"January 27, 2022","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04884308"
61,"NCT01299194","Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa",,"Completed","No Results Available","BRONCHIECTASIS","Drug: ATORVASTATIN","The primary endpoint of this study is a reduction in cough at 3 months compared to baseline as measured by the Leicester Cough Questionnaire score.|pulmonary physiology and assessment of exercise capacity|24 hour sputum volume|qualitative and quantitative bacteriology|health related quality of life and health care utilisation|exacerbation frequency|safety of statin therapy|Airways and systemic inflammation","University of Edinburgh|NHS Lothian","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2010-022042-24","November 2010","June 2015","May 2017","February 18, 2011",,"May 3, 2017","Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01299194"
62,"NCT01818544","Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: BAY85-8501|Drug: Placebo","Number Of Subjects Who Need To Discontinue Study Medication Due To Findings In Physical Examination|Change From Baseline in Systolic Blood Pressure At Days 7, 14, 21, 28, 56|Change From Baseline in Diastolic Blood Pressure At Days 7, 14, 21, 28, 56|Change From Baseline in Heart Rate At Days 7, 14, 21, 28, 56|Number of Subjects With new Abnormal (Pathologic) Electrocardiogram (ECG) Findings From Baseline to Day 28|Number of Subjects who Show Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Bilirubin (TB) Abnormalities in Their Safety Lab Assessment|Number of Subjects With Drug Related Adverse Events as a Measure of Safety And Tolerability|Change From Baseline in Pulmonary Function Test Forced Expired Volume in 1 Second (FEV1) At Days 7, 14, 21, 28, 56|Change From Baseline in Pulmonary Function Test Forced Vital Capacity (FVC) at Days 7, 14, 21, 28, 56|Change From Baseline in Pulmonary Function Test Forced Expiratory Flow Over the Middle Half of Subject's Forced Vital Capacity (FVC) (FEF2575) at Days 7, 14, 21, 28, 56|Change From Baseline in Total Score on St. George's Respiratory Questionnaire (SGRQ) at Day 28 and 56|Change From Baseline in 24 Hours Sputum Weight at Day 28|Change From Baseline of Biomarkers in Sputum at Days 14, 28, 56: Alpha1 Antitrypsin Human Neutrophil Elastase (A1AHNE) Complex, Interleukin-8(IL-8)|Change From Baseline of Biomarkers in Sputum at Days 14, 28, 56: Neutrophil cell Count|Change From Baseline of Human Neutrophil Elastase (NE) Activity in Sputum at Days 14, 28, 56|Change From Baseline of Human Neutrophil Elastase (NE) Concentration in Sputum at Days 14, 28, 56|Change From Baseline of Biomarkers in Blood at Days 14, 28, 56: C-reactive Protein|Change From Baseline of Biomarkers in Blood at Days 14, 28, 56: Interleukin-8 (IL8)|Change From Baseline of Biomarkers in Blood at Days 14, 28, 56: Neutrophil cell Count|Change From Baseline of Biomarkers in Urine At Days 14, 28, 56: Creatinine|Change From Baseline of Biomarkers in Urine at Days 14, 28, 56: Desmosine|Change From Baseline of Biomarkers in Urine at Days 14, 28, 56: Normalized Desmosine Value to Creatinine","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","94","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16359|2012-004491-18","April 2013","June 2014","June 2014","March 26, 2013",,"July 9, 2015","Nice, France|Perpignan, France|Donaustauf, Bayern, Germany|Rüdersdorf, Brandenburg, Germany|Hannover, Niedersachsen, Germany|Leipzig, Sachsen, Germany|Großhansdorf, Schleswig-Holstein, Germany|Kiel, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Jena, Thüringen, Germany|Hamburg, Germany|Orbassano, Torino, Italy|Genova, Italy|Milano, Italy|Napoli, Italy|Padova, Italy|Siena, Italy|Badalona, Barcelona, Spain|Salt, Girona, Spain|Majadahonda, Madrid, Spain|Madrid, Spain|Southampton, Hampshire, United Kingdom|Cottingham, Humberside, United Kingdom|Leicester, Leicestershire, United Kingdom|Liverpool, Merseyside, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Dundee, Tayside, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|South Shields, Tyne and Wear, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Bradford, West Yorkshire, United Kingdom|Glasgow, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01818544"
63,"NCT02661438","Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo",,"Completed","No Results Available","Bronchiectasis|Pulmonary Disease, Chronic Obstructive","Drug: Placebo to Ciprofloxacin DPI (BAYQ3939)","The user performed the inhalation task based on the given instructions properly (Yes/No).|The user performed the inhalation task safely (Yes/No).|DPI (Dry powder for inhalation) device malfunction (Yes/No).|Subject's subjective feedback (paraphrased) on use-safety and usability|Inhalation time|User friendliness","Bayer|Novartis","All","40 Years and older   (Adult, Older Adult)","Not Applicable","46","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18253","January 12, 2016","March 17, 2016","March 17, 2016","January 22, 2016",,"December 19, 2018","Vero Beach, Florida, United States|Jamaica, New York, United States",,"https://ClinicalTrials.gov/show/NCT02661438"
64,"NCT02411981","Effects of Chest Physiotherapy (CPT) on Lung Clearance Index (LCI) in Non Cystic Fibrosis (CF) Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Other: Autogenic drainage","Change of Lung Clearance Index (LCI)|Change of Spirometry|Sputum weight","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","All","18 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","StLuc MBWN2 03","April 2015","October 2015","February 2016","April 8, 2015",,"March 22, 2016","Cliniques universitaires Saint-Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT02411981"
65,"NCT02563197","Inhalation Flow Rate-study",,"Completed","No Results Available","Bronchiectasis","Device: T-326 Inhaler","Peak inspiratory flow (L/min)|Inspiratory volumes (V in L)|Inspiratory time (t in s)","Bayer|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17607|CIV-15-07-013749","November 23, 2015","February 17, 2016","April 29, 2016","September 30, 2015",,"April 26, 2017","Gauting, Bayern, Germany|Landsberg, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Neu-Isenburg, Hessen, Germany|Hannover, Niedersachsen, Germany|Grosshansdorf, Germany",,"https://ClinicalTrials.gov/show/NCT02563197"
66,"NCT00885521","Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Other: Exercise","Incremental Shuttle Walk Test Chronic Respiratory Disease questionnaire|6-Minute Walk Test","Bayside Health|Austin Health|Sir Charles Gairdner Hospital|Curtin University","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","348/08","February 2009","February 2013","February 2013","April 22, 2009",,"March 11, 2014","The Alfred, Melbourne, Victoria, Australia|Austin Health, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT00885521"
67,"NCT01684683","The Effect of Theophylline in the Treatment of Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: Theophylline|Drug: Placebo(for Theophylline)","Scores of the St.George's Respiratory Questionnaire|The Number of Exacerbations|Scores of The Leicester Cough Questionnaire|24 Hour Sputum Volume|Activity of histone deacetylase(HDAC)|Activity of histone acetyltransferase(HAT)|Lung function|Induced sputum culture|Induced Sputum Cytology Count|Interleukin-6(IL-6)|C-Reactive Protein|To evaluate change in patients' Clinical Data|Number of participants with adverse events|Plasma Concentration of Theophylline|IL-8|IL-10|Human Tumor Necrosis Factor α（TNF-α)|8-Isoprostane|Blood routine examination","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","theophylline in NCFB","November 2012","April 2014","September 2014","September 13, 2012",,"March 11, 2015","State Key Laboratory of Respiratory Research Institute., Guangzhou City, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01684683"
68,"NCT00749866","Long Term Nebulised Gentamicin in Patients With Bronchiectasis",,"Completed","No Results Available","Bronchiectasis","Drug: Gentamicin|Drug: Saline","Reduction in bacterial load|airways and systemic inflammation|Spirometry and exercise capacity|Exacerbation frequency|Health Related Quality of Life|Long term safety with nebulised Gentamicin","University of Edinburgh|NHS Lothian","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CZB/4/451","May 2007","August 2009","August 2009","September 9, 2008",,"August 10, 2010","Royal Infirmary of Edinburgh, Edinburgh, Lothian, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00749866"
